Large-scale testing of AIDS vaccines could begin in two years and a vaccine could be widely available by the middle of the 1990s, researchers said Friday.

In an address at the Sixth International Conference on AIDS, Dr. Jay A. Berzofsky of the National Cancer Institute said the most effective vaccines will probably be synthetic - made through recombinant DNA technology, or genetic engineering."We're now in a position to take advantage of recent advantages in immunology to design an artificial vaccine," Berzofsky said. "And it should be possible to develop such a vaccine in the near future."

The AIDS vaccine group led by Dr. Jonas Salk reported that the Salk AIDS vaccine has so far produced beneficial blood changes in some of the 19 patients with AIDS-related complex who received it. The significance of those changes is still being studied, said Alexandra M. Levine of the University of Southern California.

[Dr. Wayne C. Koff (born 1952)], chief of the AIDS vaccine research branch at the National Institute of Allergy and Infectious Diseases, said the most promising human vaccines should be ready for large-scale testing in two or three years, and it will take two or three more years to determine their effectiveness.

"So, we're still looking at the mid-to-late 1990s as a minimal time frame for selection of a vaccine for general use," Koff said.

Some 30 approaches toward the development of vaccines are now being studied, Koff said. Half a dozen vaccines are already being tested or are about to be tested in humans, he said.

Optimism about an AIDS vaccine is spurred by recent successes with vaccines in animals, said [Dr. Murray Briggs Gardner (born 1945)] of the University of California, Davis.

A San Francisco community research group reported improvement in AIDS patients given a drug called compound Q, derived from a Chinese herb. Before getting the drug, patients suffered a steady decline in immune system cells called CD4 cells. Afterward, 38 of the patients showed either a stabilization of CD4 cells or an increase , said the study's director, Martin Delaney.

"At this stage, we have seen a major and dramatic change in what happens to these patients," Delaney said. But he said he could not yet recommend that the drug be taken widely because of potentially dangerous side effects.

Near the Moscone Center convention hall, more than 200 protesters, mostly woman, gathered in the latest of a string of daily demonstrations sponsored by ACT UP, the AIDS Coalition To Unleash Power.

Friday's demonstration focused on what ACT UP contends is the exclusion of women, children and minorities from research, treatment and other services.

Many protesters bound themselves to metal barricades with symbolic red paper chains, chanting, "Women die faster, this is a disaster," and waved signs reading "Health Care Now," Women Gets AIDS Too."

Optimistic after a string of laboratory successes, researchers are assembling potential vaccines against AIDS and may start preliminary testing within a year, scientists at the Sixth International Conference on AIDS said today.

In sessions so crowded that some people were turned away, researchers on Friday reviewed their most hopeful work, steps they have taken toward creating a vaccine that could prevent spread of the human immunodeficiency virus.

''In the past year, we've cracked open the door in our optimism about a vaccine,'' said [Dr. Wayne C. Koff (born 1952)], chief of vaccine research at the National Institute of Allergies and Infectious Diseases. ''And I think in the next two or three years we will knock it down.''

Some of the experiments came after dozens of failed experiments in animals since 1986, failures that produced a deep pessimism about whether a vaccine would ever be possible.

Pregnant Women as Subjects

Reports given at the meeting demonstrated that monkeys, chimpanzees, cats and cells in an artificial human immune system can be protected against infection. These early experiments will continue, Dr. Koff said at a news conference after the Friday session, but it is also urgent to begin tests as soon as possible.

He said that within a year, researchers may begin experiments in which a vaccine will be used to treat pregnant women already infected with the virus. The researchers hope the vaccine may retard the development of disease in the women and may prevent them from passing the infection to their babies, Dr. Koff said. About one-third of the babies born to infected women acquire the disease in the womb.

Tests of the more conventional use of a vaccine, to protect the population against infection, are not likely to begin for two to four years. Researchers said how long it would take to create a working vaccine depended on success at each step along the way, though there is now hope that one may be on the market in 10 years.

Progress and Difficulties

Vaccine research was the topic of several sessions at the conference over three days ending today. [Dr. Jay Arthur Berzofsky (born 1946)], chief of immunogenetics and vaccine research at the National Cancer Institute, outlined the progress and difficulties to those at the conference Friday and elaborated on those points in an interview today.

The recent successes demonstrate that a vaccine in humans is at least feasible, Dr. Berzofsky said.

Results from three successful chimpanzee experiments and three successful monkey experiments were reported at the meeting, but Dr. Berzofsky said the success was limited. In each experiment, the animals were given a vaccine, then given doses of the live virus, and the researchers found that the animals were protected against infection by the virus.

Two Types of Infection

Dr. Berzofsky said that the doses of live virus given to the animals were low and that the virus was given in shots, whereas actual human infection occurs through the skin of the genitals or elsewhere.

Also, he said, only the virus itself was given to the animals, while humans are infected by such free virus as well as virus hidden inside infected cells in the blood or sperm. The body has different means of responding to each type of infection.

It is not known if the animal tests would be successful if they were given both free virus and cell-carried virus, Dr. Berzofsky said.

[Dr. Jay A. Levy (born 1938)], a virologist at the University of California at San Francisco, said, ''That will be one of the most important experiments to do now. When animals are protected from cell-associated virus, that will be a real breakthrough,'' he said.

Successes and Failures

One series of experiments reported here explored the difference between the failed experiments of previous years and the successful ones of the past year.

Researchers from Genentech, a California biotechnology company, reported that in 1986 they had taken a portion of the outer shell of the virus and injected it to make the chimpanzees' immune system produce antibodies and killer cells as if a viral attack was under way.

But after the vaccination, when live virus was given to the chimp, the protection failed and the animal quickly became infected.

Beginning in 1989, the group changed its approach. Researchers around the country began to report that a crucial segment of the viral shell, called the Third Variable region, or V3 loop, is the most powerful in creating defenses against the virus.

The Genentech group found that in its earlier experiments that region had been snipped in half by enzyme, and was disabled. In the new experiments they made sure the V3 loop was intact. The experiments succeeded, and two chimpanzees were protected by the new vaccine.

Infection Is Quickened

Researchers at a competing company, [MicroGeneSys, Incorporated] of Boston, say there are other important active sites. In addition, each different strain of the virus has slightly different versions of these active sites, so that it will probably be necessary to assemble a vaccine that includes bits of active sites from five or six different strains.

The Genentech team also noted a potential danger in the vaccine work in general: When the immune system makes antibodies to protect itself, some antibodies, ''enhancing antibodies,'' actually do the opposite and may dramatically speed up the progession of disease.

In a chimpanzee experiment that failed to protect the animals, Genentech researchers saw that the animals became infected twice as fast as might normally be expected.

In order to overcome the problem, the researchers say, a vaccine must not include bits of the shell that will elicit ''enhancing antibodies.''

About 30 Vaccine Candidates

There are now about 30 vaccine candidates being tested in laboratories around the world, and about $180 million is being expended on the work, Dr. Koff said, including $150 million for research and $30 million for preliminary safety tests being done in humans.

At the meeting, two groups, one led by Dr. Jonas Salk, creator of the Salk polio vaccine, and Dr. Alexandra Levine of the University of Southern California, and the other led by Dr. Robert Redfield of the Walter Reed Army Medical Center, reported that giving vaccines to humans produces a substantial immune response without significant side effects.

In the work presented by Dr. Levine, 82 patients already infected with the virus were given a vaccine created from a live but disabled AIDS virus. Among the 82, given the vaccine at various times over the past two years, only one has developed an infection characteristic of AIDS, and five have developed Kaposi's sarcoma, the cancer associated with AIDS.

The experiment had no comparison group, so no conclusions may be drawn, but it appears that rate of progression to disease is about a fifth of the rate found in other experimental groups.

Beth Elise Anisman and Alexander Eric Berzofsky were married Monday afternoon at the Black Point Inn in Scarborough, Me. Rabbi Kopi Saltman, the stepfather of the bride, officiated.

The bride, 35, is the senior real estate lawyer for Lehman Brothers in New York, where she is also the chief administrative officer of the corporate advisory division, which deals with legal compliance and audit matters. She is on the executive committee of the board of the Jewish Board of Family and Children's Services. She graduated cum laude from Barnard and received her law degree from Northwestern University.

Her father, Martin Anisman of Amherst, N.Y., is the president of Daemen College in Amherst. Her mother, Joyce Saltman of Delray Beach, Fla., and Clinton, Conn., is a professor at Southern Connecticut State University in New Haven, where she teaches graduate students how to teach special education. The bride's mother also lectures on the therapeutic value of laughter. The bride's stepfather, an ordained rabbi, retired as the principal of the Rock Hill Elementary School in Wallingford, Conn. He is now an adjunct instructor at Southern Connecticut State; he also teaches how to teach special education, but to undergraduates.

The bridegroom, 32, is a vice president of Warburg Pincus, the venture capital and investment firm in Manhattan; he handles investments in software and business services companies. He graduated cum laude from Harvard.

He is a son of Sharon M. Berzofsky and Dr. Jay A. Berzofsky of Bethesda, Md. His mother retired as a program manager there for a computer software unit of I.B.M. His father is the chief of the vaccine branch of the National Cancer Institute of the National Institutes of Health, also in Bethesda.

Jay A. Berzofsky :  "Cancer Vaccines: Translation from Mice to Human Clinical Trials"

• Abstract : Both the humoral and cellular immune systems can be elicited by cancer vaccines to target cancer, but antibodies can detect only surface antigens on tumor cells whereas T cells can detect fragments of any protein made in the cell, presented by HLA molecules. I will describe examples of both types of vaccines that we have translated from preclinical discovery in mice to human clinical trials. For T cell recognition, many cancer epitopes may be of too low affinity to induce a T cell response, so we developed an epitope enhancement approach to increase affinity for HLA molecules. TARP is an antigen discovered by Ira Pastan’s lab expressed in about 95% of prostate cancers of all types and stages as well as 50% of breast cancers. We mapped epitopes presented by HLA-A2, the most common human class I HLA molecule, and then modified the sequence of one with intermediate affinity to make it more immunogenic (“epitope enhancement”). The enhanced epitope induced T cells in HLA-A2 transgenic mice reactive with the natural sequence more effectively than the natural sequence itself, and induced human T cells that killed human tumor cells expressing TARP and HLA-A2. Two peptides were translated into a clinical trial in stage D0 prostate cancer, the stage in which the primary tumor has been removed but a rising PSA indicates microscopic recurrence. In this setting, in which no tumor can be measured radiographically, the rate of change of PSA has been validated as a measure of clinical outcome. In patients receiving the TARP peptide vaccine, nearly three-fourths had a statistically significantly decreased PSA slope at 6 and 12 months, and the median tumor growth rate constant was reduced in half. A follow-up randomized, placebo-controlled phase II trial is underway. The vaccine targeting antibodies is a recombinant adenovirus expressing the extracellular and transmembrane domains of HER2. In mice, such a vaccine cured virtually 100% of large established murine mammary carcinomas, and cured mice of large established lung metastases. In mice, the therapeutic effect was independent of CD8 T cells but completely dependent on antibodies. However, the mechanism was different from that of trastuzumab in that it was not FcR-dependent. A human version was used to transduce autologous dendritic cells to treat patients with any type of HER2-positive tumor not previously treated with HER2-directed therapy. Early results show several objective clinical responses. Thus, cancer vaccines eliciting either T cells or antibodies have great promise to treat cancer and may be amplified by synergy with other agents such as checkpoint inhibitors.

• Biography : Dr. Jay A. Berzofsky, National Cancer Institute, USA, Chief of the Vaccine Branch, CCR, NCI, former president of the American Society for Clinical Investigation and former Chair of the Medical Sciences Section of AAAS, who won the NIH Director’s Award and NCI Merit Award in 2008 and a Merit Award in 2011.

Sharon Berzofsky was working in her garden when a group of Russians showed up with an interpreter and asked if they could buy her Bethesda house. She told them that it wasn’t for sale, but gave them a tour of the property anyway.

“They called me back, and they made me an offer,” Berzofsky said. “They wanted to give me a suitcase full of money.”

Another time, she recalled, she was approached by the president of the National Audubon Society, who was interested in the property because “this is the ideal house for birdwatching.”

Berzofsky understands the attraction to her home of 26 years. The Tudor-style house has unusual architectural features, and natural areas on and around the property buffer it from the hustle of nearby downtown Bethesda.

The family gave her husband a tree a year for his birthday, and many now tower over the nearly one-acre property. There are also rhododendrons and other perennials that Berzofsky said return every year “like old friends coming for a visit.” A pond on a neighboring property is home to ducks, turtles, koi and great blue herons.

The property, priced at nearly $2.5 million, has had some prominent owners. Architect Harry Edwards, known for high-end apartment complexes and single-family houses like those in Bethesda’s Greenwich Forest neighborhood, built this house in 1939 for his own home.

“He put his personality into it,” Berzofsky said. “Almost every place you look, there is something a little bit special and a little bit surprising.” She was referring to such details as the twisting back staircase and the entryway turret with a skylight, “flooding the front hallway with sunlight.”

The house was later owned by Michael Whitney Straight, a member of the philanthropic Whitney family and a confessed KGB spy, and Nina Auchincloss, stepsister to Jacqueline Kennedy Onassis.

• Notes : 

• Michael Whitney Straight (September 1, 1916 – January 4, 2004)  : https://en.wikipedia.org/wiki/Michael_Straight 

• https://en.wikipedia.org/wiki/Nina_Auchincloss_Straight

• Nina Gore Auchincloss was born in 1937[4] to [Hugh Dudley Auchincloss (born 1897)] (1897–1976) and Nina (née Gore) Auchincloss (1903–1978). 

The stone-and-brick house’s front door opens to a foyer in the turret with the skylight. The foyer provides access to the rest of the first floor and to stairs to the second floor (with its eye-catching curved landing) and the lower level.

The first floor has the kitchen, dining room, family room and powder room — also a sunroom, a den and a guest suite. The family room has exposed chestnut beams, an oak floor and a fireplace. The sunroom has three walls of windows and looks out on the pond. The renovated kitchen has new appliances, new custom cabinetry and a new butler’s pantry. It’s attached to a breakfast space with a floor-to-ceiling window looking out on the garden.

The guest suite on this floor has two bedrooms, a bathroom and a sitting room.

The primary bedroom suite, on the second floor, has two walk-in closets and two en suite full bathrooms. Three more bedrooms, three more bathrooms and a sitting room are on this floor. There is attic storage space on the third floor. The finished lower level has a laundry room, a bathroom and an office (or library) with a slate fireplace, built-in shelves and access to a patio.

The lower-level office (or library) has floor-to-ceiling windows. (Will Hinostroza)

The house is shaped like a Y, a feature that allows for more windows. “That’s why we have these wonderful views of the gardens,” Berzofsky said. “Outside every window is a landscaping focal point, so your attention is drawn from inside the house to the outside of the house.”

Berzofsky said the property is well suited for indoor and outdoor entertaining. “I can’t tell you how difficult it is both to leave the house and pack up everything,” Berzofsky said. “We’re secretly hoping that it doesn’t sell and that we get to stay here.”

BIBLIOGRAPHY  Jay Arthur Berzofsky

• 1. Nitowsky, H.M., L. Matz, and J.A. Berzofsky. 1966. Studies on oxidative drug metabolism in the full-term newborn infant. J. Pediatrics 69:1139-1149.
• 2. Berzofsky, J.A., J. Peisach, and W.E. Blumberg. 1971. Sulfheme proteins. I. Optical and magnetic properties of sulfmyoglobin and its derivatives. J. Biol. Chem. 246:3367-3377.
• 3. Peisach, J., J.A. Berzofsky, and W.E. Blumberg. 1973. Electronic control of oxygen binding to heme proteins. In Proceedings of the Second International Symposium on Oxidases and Related Oxidation-Reduction Systems. T.E. King, H.S. Mason, and M. Morrison, editors. University Park Press, Baltimore. 265-278.
• 4. Berzofsky, J.A. 1971. The nature of sulfmyoglobin: Chemical, physical, and oxygen-binding properties. Albert Einstein College of Medicine, New York.
• 5. Berzofsky, J.A., J. Peisach, and W.E. Blumberg. 1971. Sulfheme proteins II. The reversible oxygenation of ferrous sulfmyoglobin. J. Biol. Chem. 246:7366-7372.
• 6. Berzofsky, J.A., J. Peisach, and J.O. Alben. 1972. Sulfheme proteins. III. Carboxysulfmyoglobin: The relation between electron withdrawal from iron and ligand binding. J. Biol. Chem. 247:3774-3782.
• 7. Berzofsky, J.A., J. Peisach, and B.L. Horecker. 1972. Sulfheme proteins. IV. The stoichiometry of sulfur incorporation and the isolation of sulfhemin, the prosthetic group of sulfmyoglobin. J. Biol. Chem. 247:3783-3791.
• 8. Berzofsky, J.A., A.N. Schechter, and H. Kon. 1976. Does Freund`s adjuvant denature protein antigens? EPR studies of emulsified hemoglobin. J. Immunol. 116:270-273.
• 9. Berzofsky, J.A., J.G. Curd, and A.N. Schechter. 1976. Probability analysis of the interaction of antibodies with multideterminant antigens in radioimmunoassay: application to the amino terminus of the beta chain of hemoglobin S. Biochem 15:2113-2121.
• 10. Berzofsky, J.A., A.N. Schechter, G.M. Shearer, and D.H. Sachs. 1977. Genetic control of the immune response to staphyloccal nuclease III. Time course and correlation between the response to native nuclease and the response to its polypeptide fragments. J. Exp. Med. 145:111-112.
• 11. Berzofsky, J.A., A.N. Schechter, G.M. Shearer, and D.H. Sachs. 1977. Genetic control of the immune response to staphylococcal nuclease IV. H-2-linked control of the relative proportions of antibodies produced to different determinants of native nuclease. J. Exp. Med. 145:123-145.
• 11
• 12 Sachs, D.H., J.A. Berzofsky, C.G. Fathman, D.S. Pisetsky, A.N. Schechter, and R.H. Schwartz. 1976. The immune response to staphylococcal nuclease: A probe of cellular and humoral antigen specific receptors. Cold Spring Harbor Symp. Quant. Biol. 41:295-306.
• 13. Berzofsky, J.A., R.H. Schwartz, A.N. Schechter, and D.H. Sachs. 1978. H-2 linked control of the antibody and cellular immune response to nuclease at the level of individual regions of the molecule. In Ir Genes and Ia Antigens (Proceedings of the Third Ir Gene Workshop, December, 1976, Asilomar, CA). H.O. McDevitt, editor. Academic Press, New York. 423-431.
• 14. Berzofsky, J.A. 1978. Genetic control of the immune response to mammalian myoglobins in mice I. More than one I-region gene in H-2 controls the antibody response. J. Immunol. 120(2):360-369.
• 15. Pisetsky, D.S., J.A. Berzofsky, and D.H. Sachs. 1978. Genetic control of the immune response to staphylococcal nuclease. VII. Role of non-H-2-linked genes in the control of the anti-nuclease antibody response. J. Exp. Med. 147(2):396-408.
• 16. Berzofsky, J.A. 1978. The assessment of antibody affinity from radioimmunoassay. Clinical Chem. 24(3):419-421.
• 17. Berzofsky, J.A. 1978. Genetic control of the antibody response to sperm whale myoglobin in mice. Adv. Exp. Med. Biol. 98:225-240.
• 18. Berzofsky, J.A., D.S. Pisetsky, R.H. Schwartz, A.N. Schechter, and D.H. Sachs. 1978. Genetic control of the immune response to staphylococcal nuclease in mice. Adv. Exp. Med. Biol. 98:241-258.
• 19. Schwartz, R.H., J.A. Berzofsky, C.L. Horton, A.N. Schechter, and D.H. Sachs. 1978. Genetic control of the T-lymphocyte proliferative response to staphylococcal nuclease. Evidence for multiple MHC-linked Ir gene control. J. Immunol. 120:1741-1749.
• 20. Sachs, D.H., J.A. Berzofsky, D.S. Pisetsky, and R.H. Schwartz. 1978. Genetic control of the immune response to staphylococcal nuclease. In Seminars in Immunopathology Vol.I. B. Benacerraf, editor. Springer-Verlag, New York. 51-83.
• 21. Berzofsky, J.A., L.K. Richman, and D.J. Killion. 1979. Distinct H-2-linked Ir genes control both antibody and T cell responses to different determinants on the same antigen, myoglobin. Proc. Natl. Acad. Sci. U. S. A. 76:4046-4050.
• 22. Richman, L.K., R.J. Klingenstein, J.A. Richman, W. Strober, and J.A. Berzofsky. 1979. The murine Kupffer cell. I. Characterization of the cell serving accessory function in antigen-specific T cell proliferation. J. Immunol. 123:2602-2609.
• 12
• 23. Richman, L.K., W. Strober, and J.A. Berzofsky. 1980. Genetic control of the immune response to myoglobin: III. Determinant-specific, two Ir gene phenotype is regulated by the genotype of reconstituting Kupffer cells. J. Immunol. 124:619-624.
• 24. Berzofsky, J.A. 1980. Immune response genes in the regulation of mammalian immunity. In Biological Regulation and Development. R.F. Goldberger, editor. Plenum Press, New York. 467-594.
• 25. Berzofsky, J.A., G. Hicks, J. Fedorko, and J. Minna. 1980. Properties of monoclonal antibodies specific for determinants of a protein antigen, myoglobin. J. Biol. Chem. 255:11188-11191.
• 26. Berzofsky, J.A., L.K. Richman, and W. Strober. 1982. Determinant-specific antigen presentation by liver Kupffer cells under control of H-2-linked Ir genes. In Recent Advances in Mucosal Immunity. W. Strober, L.A. Hanson, and K.W. Sell, editors. Raven Press, New York. 213-223.
• 27. Berzofsky, J.A., and A.N. Schechter. 1981. The concepts of crossreactivity and specificity in immunology. Molec. Immunol. 18:751-763.
• 28. Berzofsky, J.A., and L.K. Richman. 1981. Genetic control of the immune response to myoglobins. IV. Inhibition of determinant-specific Ir-gene-controlled antigen presentation and induction of suppression by pretreatment of presenting cells with anti-Ia antibodies. J. Immunol. 126:1898-1904.
• 29. Berzofsky, J.A., G.K. Buckenmeyer, G. Hicks, F.R.N. Gurd, R.J. Feldmann, and J. Minna. 1982. Topographic antigenic determinants recognized by monoclonal antibodies to sperm whale myoglobin. J. Biol. Chem. 257:3189-3198.
• 30. Berzofsky, J.A., D.S. Pisetsky, D.J. Killion, G. Hicks, and D.H. Sachs. 1981. Ir genes of different high responder haplotypes for staphylococcal nuclease are not allelic. J. Immunol. 127:2453-2455.
• 31. Berzofsky, J.A., G.K. Buckenmeyer, G. Hicks, D.J. Killion, I. Berkower, Y. Kohno, M.A. Flanagan, M.R. Busch, R.J. Feldmann, J. Minna, and F.R.N. Gurd. 1983. Topographic antigenic determinants detected by monoclonal antibodies to myoglobin. In Protein Conformation as Immunological Signal. F. Celada, E. Sercarz, and V. Shumaker, editors. Plenum Press, New York. 165-180.
• 32. Berkower, I., G.K. Buckenmeyer, F.R.N. Gurd, and J.A. Berzofsky. 1983. A possible immunodominant domain of myoglobin for murine T lymphocytes. In Protein Conformation as Immunological Signal. F. Celada, E. Sercarz, and V. Shumaker, editors. Plenum Press, New York. 289-302.
• 33. Berzofsky, J.A., G.K. Buckenmeyer, and G. Hicks. 1982. Genetics control of the immune response to myoglobins. VI. Distinct Ir genes for different myoglobins: Complementing genes in I-A and H-2D for equine myoglobin. J. Immunol. 128:737-741.
• 13
• 34. Kohno, Y., I. Berkower, J. Minna, and J.A. Berzofsky. 1982. Idiotypes of anti-myoglobin antibodies: Shared idiotypes among monoclonal antibodies to distinct determinants of sperm whale myoglobin. J. Immunol. 128:1742-1748.
• 35. Berzofsky, J.A., and I. Berkower. 1983. Antigen-Antibody Interaction. In Fundamental Immunology. W.E. Paul, editor. Raven Press, New York. 595-644.
• 36. Kohno, Y., and J.A. Berzofsky. 1982. Genetic control of the immune response to myoglobin. V. Antibody production in vitro is macrophage and T cell-dependent and is under control of two determinant-specific Ir genes. J. Immunol. 128:2458-2464.
• 37. Lando, G., J.A. Berzofsky, and M. Reichlin. 1982. Antigenic structure of sperm whale myoglobin: I. Partition of specificities between antibodies reactive with peptides and native protein. J. Immunol. 129:206-211.
• 38. Berkower, I., G.K. Buckenmeyer, F.R.N. Gurd, and J.A. Berzofsky. 1982. A possible immunodominant epitope recognized by murine T lymphocytes immune to different myoglobins. Proc. Natl. Acad. Sci. U. S. A. 79:4723-4727.
• 39. Kohno, Y., and J.A. Berzofsky. 1982. Genetic control of the immune response to myoglobins. Both low and high responder T cells tolerant to the other MHC help high but not low responder B cells. J. Exp. Med. 156:791-809.
• 40. Simmerman, H.K.B., C.C. Wang, E.M. Horwitz, J.A. Berzofsky, and F.R.N. Gurd. 1982. Semisynthesis of sperm whale myoglobin by fragment condensation. Proc. Natl. Acad. Sci. U. S. A. 79:7739-7743.
• 41. Kohno, Y., and J.A. Berzofsky. 1982. Genetic control of immune response to myoglobin. Ir gene function in genetic restriction between T and B lymphocytes. J. Exp. Med. 156:1486-1501.
• 42. Berzofsky, J.A., Y. Kohno, and H. Kawamura. 1983. Both low and high responder myoglobin-specific T cells, tolerant to F1, help high but not low responder B cells. In Ir Genes: Past, Present, and Future. C.W. Pierce, S.E. Cullen, J.A. Kapp, B.D. Schwartz, and D.C. Shreffler, editors. Humana Press, New Jersey. 269-275.
• 43. Berzofsky, J.A. 1983. T-B reciprocity: An Ia-restricted epitope-specific circuit regulating T cell-B cell interaction and antibody specificity. Survey of Immunol. Res. 2:223-229.
• 44. Berzofsky, J.A. 1984. Monoclonal antibodies as probes of antigenic structure. In Monoclonal Antibodies as Probes of Antigenic Structure, Receptor Biochemistry and Methodology Vol. 4. J.C. Venter, C.M. Fraser, and J.M. Lindstrom, editors. Alan R. Liss, Inc., New York. 1-19.
• 45. Berzofsky, J.A. 1983. T cell activation by antigen. Immunol. Today 4:299-301.
• 14
• 46. Venter, J.C., J.A. Berzofsky, J. Lindstrom, S. Jacobs, C.M. Fraser, L.D. Kohn, W. Schnieder, G.L. Greene, A.D. Strosberg, and B.F. Erlanger. 1984. Monoclonal and anti-idiotypic antibodies as probes for receptor structure and function. Fed. Proc. 43:2534-2539.
• 47. Berzofsky, J.A. 1984. Mechanisms of antigen-specific, genetically restricted, T cell-B cell interaction. Survey of Immunol. Res. 3:103-106.
• 48. Benjamin, D.C., J.A. Berzofsky, I.J. East, F.R.N. Gurd, C. Hannum, S.J. Leach, E. Margoliash, J.G. Michael, A. Miller, E.M. Prager, M. Reichlin, E.E. Sercarz, S.J. Smith-Gill, P.E. Todd, and A.C. Wilson. 1984. The antigenic structure of proteins: A reappraisal. Annu. Rev. Immunol. 2:67-101.
• 49. Berkower, I., L.A. Matis, G.K. Buckenmeyer, F.R.N. Gurd, D.L. Longo, and J.A. Berzofsky. 1984. Identification of distinct predominant epitopes recognized by myoglobin-specific T cells under control of different Ir genes and characterization of representative T-cell clones. J. Immunol. 132:1370-1378.
• 50. Kawamura, H., Y. Kohno, M. Busch, F.R.N. Gurd, and J.A. Berzofsky. 1984. A major anti-myoglobin idiotype: Influence of H-2-linked Ir genes on idiotype expression. J. Exp. Med. 160:659-678.
• 51. Streicher, H.Z., I.J. Berkower, M. Busch, F.R.N. Gurd, and J.A. Berzofsky. 1984. The role of antigen conformation in determining requirements for antigen processing for T cell activation. In Regulation of the Immune System. E. Sercarz, H. Cantor, and L. Chess, editors. Alan R. Liss, Inc., New York. 163-180.
• 52. Berzofsky, J.A., and H.M. Grey. 1984. MHC-restricted specific antigen presentation to different T cell sets (Th, Ts, Tc). In Regulation of the Immune System. E. Sercarz, H. Cantor, and L. Chess, editors. Alan R. Liss, Inc., New York. 189-193.
• 53. Streicher, H.Z., I.J. Berkower, M. Busch, F.R.N. Gurd, and J.A. Berzofsky. 1984. Antigen conformation determines processing requirements for T-cell activation. Proc. Natl. Acad. Sci. U. S. A. 81:6831-6835.
• 54. Berzofsky, J.A., and K. Yokomuro. 1985. Antigen presenting cells: Workshop Summary. In Immune Regulation. M. Feldmann, and N.A. Mitchison, editors. Humana Press, NJ. 369-374.
• 55. Kohno, Y., H. Kawamura, and J.A. Berzofsky. 1985. A unidirectional carrier effect. Cellular Immunol. 92:226-234.
• 56. Berzofsky, J.A. 1985. The nature and role of antigen processing in T cell activation. In The Year in Immunology 1984-1985. J.M. Cruse, and R.E. Lewis, Jr., editors. Karger, Basel. 18-24.
• 15
• 57. Morrissey, P.J., S.O. Sharrow, Y. Kohno, J.A. Berzofsky, and A. Singer. 1985. Correlation of intrathymic tolerance with intrathymic chimerism in neonatally tolerized mice. Transplant. 40:68-72.
• 58. Kawamura, H., S.A. Rosenberg, and J.A. Berzofsky. 1985. Immunization with antigen and interleukin-2 in vivo overcomes Ir genetic low responsiveness. J. Exp. Med. 162:381-386.
• 59. Berkower, I., H. Kawamura, L.A. Matis, and J.A. Berzofsky. 1985. T cell clones to two major T cell epitopes of myoglobin: Effect of I-A/I-E restriction on epitope dominance. J. Immunol. 135:2628-2634.
• 60. Delisi, C., and J.A. Berzofsky. 1985. T cell antigenic sites tend to be amphipathic structures. Proc. Natl. Acad. Sci. U. S. A. 82:7048-7052.
• 61. Berzofsky, J.A. 1985. Intrinsic and extrinsic factors in protein antigenic structure. Science 229:932-940.
• 62. Darst, S.A., C.R. Robertson, and J.A. Berzofsky. 1986. Myoglobin adsorption onto crosslinked polydimethylsiloxane. Journal of Colloid and Interface Science 111:466-474.
• 63. Berzofsky, J.A., I.J. Berkower, K.B. Cease, G.K. Buckenmeyer, H.Z. Streicher, and C. Delisi. 1986. Structural and conformational requirements for protein antigen recognition by MHC class II - restricted T cells and clones. In Modern Approaches to Vaccines. F. Brown, R. Chanock, and R. Lerner, editors. Cold Spring Harbor Laboratory, New York. 123-127.
• 64. Berzofsky, J.A., K.B. Cease, G.K. Buckenmeyer, H.Z. Streicher, C. Delisi, and I.J. Berkower. 1986. Structural and conformational requirements for Ir-gene-controlled myoglobin epitope recognition by Ia-restricted T cells and clones. In Regulation of Immune Gene Expression. M. Feldmann, and A. McMichael, editors. Humana Press, Clifton, NJ. 225-234.
• 65. Kawamura, H., and J.A. Berzofsky. 1986. Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin. J. Immunol. 136:58-65.
• 66. Streicher, H.Z., F. Cuttitta, G.K. Buckenmeyer, H. Kawamura, J. Minna, and J.A. Berzofsky. 1986. Mapping the idiotopes of a monoclonal anti-idiotypic antibodies: Detection of a common idiotope. J. Immunol. 136:1007-1014.
• 67. Berzofsky, J.A. 1987. Ir genes: antigen-specific genetic regulation of the immune response. In The Antigens. M. Sela, editor. Academic Press, New York. 1-146.
• 68. Berkower, I., G.K. Buckenmeyer, and J.A. Berzofsky. 1986. Molecular mapping of a histocompatibility - restricted immunodominant T cell epitope with synthetic and natural peptides: Implications for antigenic structure. J. Immunol. 136:2498-2503.
• 16
• 69. Berzofsky, J.A. 1986. Structural features of protein antigenic sites recognized by helper T cells: What makes a site immunodominant? In The Year in Immunology 1985-1986. J.M. Cruse, and R.E. Lewis, Jr., editors. Karger, Basel. 28-38.
• 70. Simpson, E., R. Lieberman, I. Ando, D.H. Sachs, W.E. Paul, and J.A. Berzofsky. 1986. How many class II Immune Response Genes? A reappraisal of the evidence. Immunogenetics 23:302-308.
• 71. Delisi, C., J. Cornette, H. Margalit, K. Cease, J. Spouge, and J.A. Berzofsky. 1987. The role of amphipathicity as an indicator of T cell antigenic sites on proteins. In Immunogenicity of Protein Antigens: Repertoire and Regulation. E. Sercarz, and J.A. Berzofsky, editors. CRC Press, Boca Raton. 35-42.
• 72. Berzofsky, J.A., J. Cornette, H. Margalit, I. Berkower, K. Cease, and C. Delisi. 1986. Molecular features of class II MHC-restricted T cell recognition of protein and peptide antigens: the importance of amphipathic structures. In Current Topics in Microbiology and Immunology Vol. 130. F. Melchers, and H. Koprowski, editors. Springer-Verlag, New York. 14-24.
• 73. Kawamura, H., S.O. Sharrow, D.W. Alling, D. Stephany, J. York-Jolley, and J.A. Berzofsky. 1986. IL-2 receptor expression in unstimulated murine splenic T cells: Localization to L3T4+ cells and regulation by non-H-2-linked genes. J. Exp. Med. 86:1376-1390.
• 74. Wagner, D.K., J. York-Jolley, T.R. Malek, J.A. Berzofsky, and D.L. Nelson. 1986. Antigen-specific murine T cell clones produce soluble interleukin 2 receptor on stimulation with specific antigens. J. Immunol. 137:592-596.
• 75. Good, M.F., J.A. Berzofsky, W.L. Maloy, Y. Hayashi, N. Fujii, W.T. Hockmeyer, and L.H. Miller. 1986. Genetic control of the immune response in mice to a Plasmodium facilparum sporozoite vaccine: Widespread non-responsiveness to a single malaria T epitope in highly repetitive vaccine. J. Exp. Med. 164:655-660.
• 76. Berzofsky, J.A., K.B. Cease, I.J. Berkower, H. Margalit, J. Cornette, J. Spouge, C. Spencer, G. Buckenmeyer, H. Streicher, M. Kojima, and C. Delisi. 1988. The role of MHC and amphipathic structures in T cell recognition: Features determining immunodominance. In Antigen Processing and Presentation. H. Vogel, B. Pernis, and S. Silverstein, editors. Columbia University Press, New York. 125-131.
• 77. Finnegan, A., M.A. Smith, J.A. Smith, J.A. Berzofsky, D.H. Sachs, and R.J. Hodes. 1986. The T cell repertoire for recognition of a phylogenetically distant protein antigen: peptide specificity and MHC restriction of staphylococcal nuclease specific T cell clones. J. Exp. Med. 164:897-910.
• 78. Kawamura, H., and J.A. Berzofsky. 1987. Influence of MHC-linked genes on idiotype expression. In Immunogenicity of Protein Antigens: Repertoire and Regulation Vol.2. E.E. Sercarz, and J.A. Berzofsky, editors. CRC Press, Boca Raton. 121-127.
• 17
• 79. Berzofsky, J.A., K.B. Cease, I.J. Berkower, H. Margalit, J. Cornette, and C. Delisi. 1986. Immunodominance of amphipathic peptides and their localization on the cell surface for antigen presentation to helper T cells. In Progress in Immunology V. B. Cinader, and R.G. Miller, editors. Academic Press, New York. 255-265.
• 80. Cease, K.B., I. Berkower, J. York-Jolley, and J.A. Berzofsky. 1986. T cell clones specific for an amphipathic alpha helical region of sperm whale myoglobin show differing fine specificities for synthetic peptides: A multi-view/single structure interpretation of immunodominance. J. Exp. Med. 164:1779-1784.
• 81. Cease, K.B., G. Buckenmeyer, I. Berkower, J. York-Jolley, and J.A. Berzofsky. 1986. Immunologically relevant peptide antigen exists on the presenting cell in a manner accessible to macromolecules in solution. J. Exp. Med. 164:1440-1454.
• 82. Berzofsky, J.A., and K.B. Cease. 1986. Peptide antigenic structure and localization on the surface of the presenting cell for antigen presentation. Annales de l`Institut Pasteur 137D:312-316.
• 83. Berzofsky, J.A., K.B. Cease, S. Ozaki, H. Margalit, J.L. Cornette, J. Spouge, and C. Delisi. 1987. Helper T cell immunity: Implications for vaccines. In Vaccines`87. R. Chanock, F. Brown, H. Ginsberg, and R. Lerner, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. 26-32.
• 84. Finnegan, A., and J.A. Berzofsky. 1986. Antigen recognition by T cells. Immunol. Today 7:317-319.
• 85. Spouge, J.L., H.R. Guy, J.L. Cornette, H. Margalit, K. Cease, J.A. Berzofsky, and C. Delisi. 1987. Strong conformational propensities enhance T-cell antigenicity. J. Immunol. 138:204-212.
• 86. Good, M.F., I.A. Quakyi, A. Saul, J.A. Berzofsky, R. Carter, and L.H. Miller. 1987. Human T clones reactive to the sexual stages of Plasmodium falciparum malaria: High frequency of gamete-reactive T cells in peripheral blood of non-exposed donors. J. Immunol. 138:306-311.
• 87. Coico, R.F., J.A. Berzofsky, J. York-Jolley, S. Ozaki, G.W. Siskind, and G.J. Thorbecke. 1987. Physiology of IgD. VII. Induction of receptors for IgD on cloned T cells by IgD and Interleukin 2. J. Immunol. 138:4-6.
• 88. Ozaki, S., J. York-Jolley, H. Kawamura, and J.A. Berzofsky. 1987. Cloned protein antigen-specific, Ia-restricted T cells with both helper and cytolytic activities: Mechanisms of activation and killing. Cellular Immunol. 105:301-316.
• 89. Good, M.F., J.A. Berzofsky, L. Maloy, M.N. Lunde, Y. Hayashi, N. Fujii, W.T. Hockmeyer, B. Moss, and L.H. Miller. 1987. Genetic control of the immune response to a Plasmodium falciparum sporozoite vaccine and to the Cirumsporozoite (CS) protein. In
• 18
• Vaccines`87. R. Chanock, F. Brown, H. Ginsberg, and R. Lerner, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. 81-85.
• 90. Margalit, H., J.L. Spouge, J.L. Cornette, K. Cease, C. Delisi, and J.A. Berzofsky. 1987. Prediction of immunodominant helper T-cell antigenic sites from the primary sequence. J. Immunol. 138:2213-2229.
• 91. Takacs, L., J.A. Berzofsky, J. York-Jolley, T. Akahoshi, E. Blasi, and S.K. Durum. 1987. IL 1-Induction by murine T cell clones: Detection of an IL 1-inducing lymphokine. J. Immunol. 138:2124-2131.
• 92. Good, M.F., W.L. Maloy, M.N. Lunde, H. Margalit, J.L. Cornette, G.L. Smith, B. Moss, L.H. Miller, and J.A. Berzofsky. 1987. Construction of a synthetic immunogen: use of a new T-helper epitope on malaria circumsporozoite protein. Science 235:1059-1062.
• 93. Hoffman, S.L., L.T. Cannon, J.A. Berzofsky, W.R. Majarian, J.G. Young, W.L. Maloy, and W.T. Hockmeyer. 1987. Plasmodium falciparum: Increased immunity with T cell epitope on sporozoite vaccine. Exp. Parasitology 64:64-70.
• 94. Cornette, J.L., K.B. Cease, H. Margalit, J.L. Spouge, J.A. Berzofsky, and C. Delisi. 1987. Hydrophobicity scales and computational techniques for detecting amphipathic structures in proteins. J. Mol. Biol. 195:659-686.
• 95. Cease, K.B., H. Margalit, J.L. Cornette, S.D. Putney, W.G. Robey, C. Ouyang, H.Z. Streicher, P.J. Fischinger, R.C. Gallo, C. Delisi, and J.A. Berzofsky. 1987. Helper T cell antigenic site identification in the AIDS virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc. Natl. Acad. Sci. USA 84:4249-4253.
• 96. Ozaki, S., and J.A. Berzofsky. 1987. Antibody conjugates mimic specific B cell presentation of antigen: Relationship between T and B cell specificity. J. Immunol. 138:4133-4142.
• 97. Berzofsky, J.A., K.B. Cease, J.L. Cornette, J.L. Spouge, H. Margalit, I.J. Berkower, M.F. Good, L.H. Miller, and C. Delisi. 1987. Protein antigenic structures recognized by T cells: Potential applications to vaccine design. Immunol. Rev. 98:9-52.
• 98. Berzofsky, J.A. 1988. Features of T-cell recognition and antigen structure useful in the design of vaccines to elicit T-cell immunity. Vaccines 6:89-93.
• 99. Berzofsky, J.A., and S. Ozaki. 1988. Antibody conjugates mimic specific B-cell presentation of antigen: epitope restrictions in specific T-B interaction. In Antigen Presenting Cells: Diversity, Differentiation and Regulation. L.B. Schook, and J.G. Tew, editors. Alan R. Liss, Inc., New York. 41-48.
• 100. Good, M.F., D. Pombo, I.A. Quakyi, E.M. Riley, R.A. Houghten, A. Menon, D.W. Alling, J.A. Berzofsky, and L.H. Miller. 1988. Human T cell recognition of the circumsporozoite
• 19
• protein of Plasmodium falciparum. Immunodominant T cell domains map to the polymorphic regions of the molecule. Proc. Natl. Acad. Sci. USA 85:1199-1203.
• 101. Good, M.F., J.A. Berzofsky, and L.H. Miller. 1988. The T-cell response to the malaria circumsporozoite protein: an immunological approach to vaccine development. Annu. Rev. Immunol. 6:663-688.
• 102. Lin, J., J.A. Berzofsky, and T.L. Delovitch. 1988. Ultrastructural study of internalization and recycling of antigen by antigen presenting cells. J. Mol. Cell. Immunol. 3:321-343.
• 103. Kojima, M., K.B. Cease, G.K. Buckenmeyer, and J.A. Berzofsky. 1988. Limiting dilution comparison of the repertoires of high and low responder MHC-restricted T cells. J. Exp. Med. 167:1100-1113.
• 104. Good, M.F., D. Pombo, W.L. Maloy, V.F. De la Cruz, L.H. Miller, and J.A. Berzofsky. 1988. Parasite polymorphism present within minimal T-cell epitopes of Plasmodium falciparum circumsporozoite protein. J. Immunol. 140:1645-1650.
• 105. Takahashi, H., J. Cohen, A. Hosmalin, K.B. Cease, R. Houghten, J. Cornette, C. Delisi, B. Moss, R.N. Germain, and J.A. Berzofsky. 1988. An immunodominant epitope of the HIV gp160 envelope glycoprotein recognized by class I MHC molecule-restricted murine cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA 85:3105-3109.
• 106. Darst, S.A., C.R. Robertson, and J.A. Berzofsky. 1988. Adsorption of the protein antigen myoglobin affects the binding of conformation specific monoclonal antibodies. Biophysical Journal 53:533-539.
• 107. Pombo, D., W.L. Maloy, J.A. Berzofsky, and M.F. Good. 1988. Neonatal exposure to immunogenic peptides. Differential susceptibility to tolerance induction of helper T cells and B cells reactive to malarial circumsporozoite peptide epitopes. J. Immunol. 140:3594-3598.
• 108. Berzofsky, J.A. 1988. T-cell recognition of protein and peptide antigens: applications to vaccines development. In Technological Advances in Vaccine Development. L. Laskey, editor. Alan R. Liss, Inc., New York, 587-602.
• 109. Berzofsky, J.A. 1988. Immunodominance in T lymphocyte recognition. Immunol. Letters 18:83-92.
• 110. Ozaki, S., S.K. Durum, K. Muegge, J. York-Jolley, and J.A. Berzofsky. 1988. Production of T-T hybrids from T cell clones: Direct comparison between cloned T cells and T hybridoma cells derived from them. J. Immunol. 141:71-78.
• 111. Brett, S.J., K.B. Cease, and J.A. Berzofsky. 1988. Influences of antigen processing on the expression of the T cell repertoire: Evidence for MHC-specific hindering structures on the products of processing. J. Exp. Med. 168:357-373.
• 20
• 112. Good, M.F., D. Pombo, M.N. Lunde, W.L. Maloy, R. Halenbeck, K. Koths, L.H. Miller, and J.A. Berzofsky. 1988. Recombinant human interleukin-2 (IL-2) overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biological activity of IL-2. J. Immunol. 141:972-977.
• 113. Cease, K.B., and J.A. Berzofsky. 1990. T cell immunity and vaccine engineering: Application to the AIDS virus. In AIDS Vaccine Research and Clinical Trials. S. D. Putney, and D. P. Bolognesi, editors. Marcell Dekker, New York, pp. 139-156.
• 114. Kumar, S., L.H. Miller, I.A. Quakyi, D.B. Keister, R.A. Houghten, W.L. Maloy, B. Moss, J.A. Berzofsky, and M.F. Good. 1988. Cytotoxic T cells specific for the circumsporozoite protein of Plasmodium falciparum. Nature 334:258-260.
• 115. Berzofsky, J.A., A. Bensussan, K.B. Cease, J.F. Bourge, R. Cheynier, Z. Lurhuma, J.-J. Salaün, R.C. Gallo, G.M. Shearer, and D. Zagury. 1988. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature 334:706-708.
• 116. Margalit, H., C. Delisi, and J.A. Berzofsky. 1990. Computer predictions of T-cell epitopes. In New Generation Vaccines. G.C. Woodrow, and M.M. Levine, editors. Marcel Dekker, New York, 109-116.
• 117. Berzofsky, J.A. 1989. Structural features of T-cell recognition: Applications to vaccine design. Phil. Trans. Roy. Soc. London B., 323: 535-544.
• 118. Cease, K.B., and J.A. Berzofsky. 1988. Antigenic structures recognized by T cells: Toward the rational design of an AIDS vaccine. AIDS 2:(suppl.1) S95-S101.
• 119. Berzofsky, J.A., S.J. Brett, H.Z. Streicher, and H. Takahashi. 1988. Antigen processing for presentation to T lymphocytes: Function, mechanisms, and implications for the T-cell repertoire. Immunol. Rev. 106: 5-31.
• 120. Good, M.F., L.H. Miller, S. Kumar, I.A. Quakyi, D. Keister, J. Adams, B. Moss, J.A. Berzofsky, and R. Carter. 1988. Limited immunological recognition of critical malaria vaccine candidate antigens. Science 242: 574-577.
• 121. Berzofsky, J.A., and I.J. Berkower. 1989. Immunogenicity and antigen structure. In Fundamental Immunology 2nd Edition. W.E. Paul, editor. Raven Press, New York, pp. 169-208.
• 122. Berzofsky, J.A., S.L. Epstein, and I.J. Berkower. 1989. Antigen-antibody interactions and monoclonal antibodies. In Fundamental Immunology 2nd edition. W.E. Paul, editor. Raven Press, New York, pp. 315-356.
• 123. Dontfraid, F., M.A. Cochran, D. Pombo, J.D. Knell, I. Quakyi, S. Kumar, R.A. Houghten, J.A. Berzofsky, L.H. Miller, and M.F. Good. 1988. Human and murine CD4 T-cell epitopes map to the same region of the malaria circumsporozoite protein: Limited
• 21
• immunogenicity of sporozoites and cirumsporozoite protein. Mol. Biol. Med., 5: 185-196.
• 124. Hosmalin, A.M., P.L. Nara, M. Zweig, K.B. Cease, E. Gard, P.D. Markham, S.D. Putney, M.D. Daniel, R.C. Desrosiers, and J.A. Berzofsky. 1989. Enhancement of an antibody response to the envelope glycoprotein of HIV-1 in primates by priming with helper T-cell epitope peptides. In Vaccines 89. R. Lerner, H. Ginsberg, R. Chanock, and F. Brown, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, 121-124
• 125. Takahashi, H., J. Cohen, A. Hosmalin, K.B. Cease, R. Houghten, J.L. Cornette, C. Delisi, S. Merli, B. Moss, R.N. Germain, and J.A. Berzofsky. 1989. Limited epitope repertoire recognized with class I MHC molecules by murine cytotoxic lymphocytes on the HIV gp160 envelope glycoprotein. In Vaccines 89. R. Lerner, H. Ginsberg, R. Chanock, and F. Brown, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor., 109-114.
• 126. Berzofsky, J.A. 1989. Immunodominance of T-cell epitopes: Applications to vaccine design. In Vaccines 89. R. Lerner, H. Ginsberg, R. Chanock, and F. Brown, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, 27-31.
• 127. Berzofsky, J.A. 1988. The structural basis of antigen recognition by T lymphocytes: Implications for vaccines. J. Clin. Invest. 82: 1811-1817.
• 128. Berzofsky, J.A. 1989. Mechanisms of immunodominance in T-cell recognition, with applications to vaccine design. In Immune System and Cancer: Proceedings of the Nineteenth International Symposium of the Princess Takamatsu Cancer Research Fund. T. Hamaoka, R.J. Hodes, G. Klein, T. Sugimura, S. Takayama, and Y. Yamamura, editors. The Princess Takamatsu Cancer Research Fund, Tokyo, 161-177.
• 129. Takahashi, H., K.B. Cease, and J. A. Berzofsky. 1989. Identification of proteases that process distinct epitopes on the same protein. J. Immunol. 142: 2221-2229.
• 130. Brett, S. J., D. McKean, J. York-Jolley, and J. A. Berzofsky. 1989. Antigen presentation to specific T cells by Ia molecules selectively altered by site-directed mutagenesis. Internat. Immunol. 1: 130-140.
• 131. Berzofsky, J. A., and Y. Paterson. 1990. Discussion summary: Antigen structure: B cell and T cell determinants and immunogenicity. In Immunogenicity (UCLA Symposia on Molecular and Cellular Biology, New Series, Vol. 113). C. Janeway, J. Sprent, and E. Sercarz, editors. Alan R. Liss, New York, pp. 65-67.
• 132. Hoffman, S. L., J. A. Berzofsky, D. Isenbarger, E. Zeltzer, W. R. Majarian, M. Gross, and W. R. Ballou. 1989. Immune response gene regulation of immunity to Plasmodium berghei sporozoites and circumsporozoite protein vaccines: Overcoming genetic restriction with whole organism and subunit vaccines. J. Immunol. 142: 3581-3584.
• 22
• 133. Cornette, J. L., H. Margalit, C. DeLisi, and J. A. Berzofsky. 1989. Concepts and methods in the identification of T cell epitopes and their use in the construction of synthetic vaccines. Methods in Enzymol. 178: 611-634.
• 134. Sanui, H., T. M. Redmond, S. Kotake, B. Wiggert, L.-H. Hu, H. Margalit, J. A. Berzofsky, G. J. Chader, and I. Gery. 1989. Identification of an immunodominant and highly immunopathogenic determinant in the retinal interphotoreceptor retinoid-binding protein (IRBP). J. Exp. Med. 169: 1947-1960.
• 135. DeGroot, A. S., A. H. Johnson, W. L. Maloy, I. A. Quakyi, E. M. Riley, A. Menon, S. M. Banks, J. A. Berzofsky, and M. F. Good. 1989. Human T cell recognition of polymorphic epitopes from malaria circumsporozoite protein. J. Immunol. 142: 4000-4005.
• 136. Palker, T. J., T. J. Matthews, A. Langlois, M. E. Tanner, M. E. Martin, R.M. Scearce, J. E. Kim, J. A. Berzofsky, D. P. Bolognesi, and B. F. Haynes. 1989. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. J. Immunol. 142: 3612-3619.
• 137. Sanza, L. R., L.M.Gierasch, J. A. Berzofsky, G. K. Buckenmeyer, K. B. Cease, and C. S. Ouyang. 1988. Formation of amphipathic secondary structure is correlated to T-cell antigenicity in a series of synthetic peptides from sperm whale myoglobin. In Peptides: Chemistry and Biology. G. R. Marshall, editor, ESCOM, Leiden, pp. 549-550.
• 138. Palker, T. J., T. J. Matthews, A. Langlois, J. E. Kim, J. A. Berzofsky, D. P. Bolognesi, and B. F. Haynes. 1989. Multivalent synthetic peptide inoculum induces neutralizing antibodies to divergent HIV isolates and anamnestic T-cell responses to HIV gp120. In Early Human Retroviruses. J. E. Groopman, I. Chen, M. Essex, and R. Weiss, editors. Alan R. Liss, New York, in press.
• 139. Clerici, M., N. I. Stocks, R. A. Zajac, R. N. Boswell, D. C. Bernstein, D. L. Mann, G. M. Shearer, and J. A. Berzofsky. 1989. IL-2 production used to detect antigenic peptide recognition by T helper lymphocytes from asymptomatic, HIV seropositive individuals. Nature 339: 383-385.
• 140. Williams, W.V., S.D. London, D.B. Weiner, S. Wadsworth, J.A. Berzofsky, F. Robey, D.H. Rubin, and M.I. Greene. 1989. Immune response to a molecularly defined internal image idiotope. J. Immunol. 142: 4392-4400.
• 141. Brett, S.J., K.B. Cease, C.S. Ouyang, and J.A. Berzofsky. 1989. Fine specificity of T cell recognition of the same peptide in association with different I-A molecules. J. Immunol. 143: 771-779.
• 142. Hale, P.M., K.B. Cease, R.A. Houghten, C. Ouyang, S. Putney, K. Javaherian, H. Margalit, J.L. Cornette, J.L. Spouge, C. Delisi, and J.A. Berzofsky. 1989. T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restriction. Internat. Immunol. 1: 409-415.
• 23
• 143. Berzofsky, J.A., A. Kurata, H. Takahashi, S.J. Brett, and D.J. McKean. 1989. Molecular studies of antigen processing and presentation to T cells by class II MHC molecules. In Cold Spring Harbor Symposium on Quantitative Biology LIV: Immunological Recognition. J.D. Watson, and J. R. Inglis, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, pp. 417-430.
• 144. Kurata, A., T.J. Palker, R.D. Streilein, R.M. Scearce, B.F. Haynes, and J.A. Berzofsky. 1989. Immunodominant sites of human T-cell lymphotropic virus type 1 envelope protein for murine helper T cells. J. Immunol. 143: 2024-2030.
• 145. Redmond, T.M., H. Sanui, L.H. Hu, B. Wiggert, H. Margalit, J.A. Berzofsky, G.J. Chader, and I. Gery. 1989. Immune responses to peptides derived from the retinal protein IRBP: immunopathogenic determinants are not necessarily immunodominant. Clinical Immunology and Immunopathology 53: 212-224.
• 146. Lark, L.R., J.A. Berzofsky, and L.M. Gierasch. 1989. T-Cell antigenic peptides from sperm whale myoglobin fold as amphipathic helices: a possible determinant for immunodominance? Peptide Research : 2: 314-321.
• 147. Vacchio, M.S., J.A. Berzofsky, U. Krzych, J.A. Smith, R.J. Hodes, and A. Finnegan. 1989. Sequences outside a minimal immunodominant site exert negative effects on recognition by staphylococcal nuclease-specific T-cell clones. J. Immunol. 143: 2814-2819.
• 148. Vajda, S., H. Margalit, R. Kataoka, J. L. Cornette, J. A. Berzofsky, and C. DeLisi. 1990. Molecular structure and vaccine design. Ann. Rev. Biophys. Biophys. Chem. 19: 69-82..
• 149. Takahashi, H., S. Merli, S.D. Putney, R. Houghten, B. Moss, R.N. Germain, and J.A. Berzofsky. 1989. A single amino acid interchange yields reciprocal CTL specificities for HIV gp160. Science 246: 118-121.
• 150. Takahashi, H., R. Houghten, S.D. Putney, D.H. Margulies, B. Moss, R.N. Germain, and J.A. Berzofsky. 1989. Structural requirements for class-I MHC molecule-mediated antigen presentation and cytotoxic T-cell recognition of an immunodominant determinant of the HIV envelope protein. J. Exp. Med. 170: 2023-2035.
• 151. Weiss, W.R., M.F. Good, M.R. Hollingdale, L.H. Miller, and J.A. Berzofsky. 1989. Genetic control of immunity to Plasmodium yoelii sporozoites. J. Immunol. 143: 4263-4266.
• 152. Berzofsky, J.A., P.M. Hale, M. Clerici, K.B. Cease, R.A. Houghten, S.D. Putney, R.A. Zajac, R.N. Boswell, H. Margalit, J.L. Cornette, J.L. Spouge, C. Delisi, and G.M. Shearer. 1990. Multideterminant regions of the HIV-1 envelope with sites seen by murine and human helper T cells: circumventing the MHC restriction problem. In Vaccines 90. F. Brown, R.M. Chanock, H.S. Ginsberg, and R.A. Lerner, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, pp. 307-312.
• 24
• 153. Takahashi, H., R. Houghten, S. Merli, S.D. Putney, B. Moss, R.N. Germain, and J.A. Berzofsky. 1990. Immunoodominant CTL epitope of HIV-1 envelope protein: the relationship between viral mutation and CTL specificity. In Vaccines 90. F. Brown, R.M. Chanock, H.S. Ginsberg, and R.A. Lerner, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, pp 269-276.
• 154. Vinetz, J.M., S. Kumar, M.F. Good, B.J. Fowlkes, J.A. Berzofsky, and L.H. Miller. 1990. Adoptive transfer of CD8+ T cells from immune animals does not transfer immunity to blood stage Plasmodium yoelii malaria. J. Immunol. 144: 1069-1074.
• 155. Takahashi, H., R.N. Germain, B. Moss, and J.A. Berzofsky. 1990. An immunodominant class I-restricted CTL determinant of HIV-1 induces CD4 class II-restricted help for itself. J. Exp. Med. 171: 571-576.
• 156. Weiss, W.R., S. Mellouk, R.A. Houghten, M. Sedegah, S. Kumar, M.F. Good, J.A. Berzofsky, L.H. Miller, and S.L. Hoffman. 1990. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria infected hepatocytes. J. Exp. Med. 171: 763-773.
• 157. Kotake, S., B. Wiggert, T.M. Redmond, D.E. Borst, J.M. Nickerson, H. Margalit, J.A. Berzofsky, G.J. Chader, and I. Gery. 1990. Repeated determinants within the retinal interphotoreceptor retinoid-binding protein (IRBP). Immunological properties of the repeats of an immunodominant determinant. Cellular Immunol., 126: 331-342.
• 158. Hosmalin, A., M. Clerici, R. Houghten, C.D. Pendleton, C. Flexner, D.R. Lucey, B. Moss, R.N. Germain, G.M. Shearer, and J.A. Berzofsky. 1990. An epitope in HIV-1 reverse transcriptase recognized by both mouse and human CTL. Proc. Natl. Acad. Sci. U. S. A. 87: 2344-2348.
• 159. Ahlers, J., M. Clerici, A. Hosmalin, G.M. Shearer, and J.A. Berzofsky. 1990. Host immune response: T helper cell responses. In Techniques in HIV Research. A. Aldovini, and B. Walker, editors. Stockton Press, New York, pp. 211-222.
• 160. Berzofsky, J.A. 1990. Immunogenicity of antigens recognized by T cells. In Cellular Immunity and the Immunotherapy of Cancer. M.T. Lotze, and O.J. Finn, editors. Wiley-Liss, Inc., New York, 1-22.
• 161. Takahashi, H., T. Takeshita, B. Morein, S.D. Putney, R.N. Germain, and J.A. Berzofsky. 1990. Induction of specific CD8+ class I-MHC restricted CTL against HIV envelope protein by immunization with purified whole protein in ISCOMs. Nature , 344: 873-875.
• 162. Kim, J.E., M. Kojima, R. Houghten, C.D. Pendleton, J.L. Cornette, C. Delisi, and J.A. Berzofsky. 1990. Characterization of a helper T-cell epitope recognized by mice of a low responder major histocompatibility type. Molec. Immunol. 27: 941-946.
• 163. Weiner, D.B., W.V. William, M.J. Merva, K. Huebner, J.A. Berzofsky, and M.I. Greene. 1990. HIV Infectivity analysis of viral envelope determinants and target cell requirements for infectivity by HIV-1. In Vaccines 90. F. Brown, R.M. Chanock, H.S. Ginsberg, and R.A. Lerner, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. 339-345.
• 164. Kurata, A., and J.A. Berzofsky. 1990. Analysis of peptide residues interacting with MHC molecule or T-cell receptor: can a peptide bind in more than one way to the same MHC molecule?. J. Immunol. 144: 4526-4535.
• 165. Kumar, S., J. Gorden, J.L. Flynn, J.A. Berzofsky, and L.H. Miller. 1990. Immunization of mice against Plasmodium vinckei with a combination of attenuated Salmonella typhimurium and malarial antigen. Infect. Immun. 58: 3425-3429.
• 166. Kozlowski, S., T. Takeshita, W. -H. Boehncke, H. Takahashi, L. F. Boyd, R. N. Germain, J. A. Berzofsky, and D. H. Margulies. 1991. Excess 2-microglobulin promotes functional peptide association with purified soluble class I MHC molecules. Nature 349: 74-77.
• 167. Hosmalin, A., P. L. Nara, M. Zweig, N. W. Lerche, K. B. Cease, E. A. Gard, P. D. Markham, S. D. Putney, M. D. Daniel, R. C. Desrosiers, and J. A. Berzofsky. 1991. Priming with helper T-cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV 1 in primates. J. Immunol. 146: 1667-1673.
• 168. Berzofsky, J.A. 1991. Progress towards an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization. Biotech. Therapeutics. 2: 123-135.
• 169. Berzofsky, J.A. 1991. Approaches and issues in the development of vaccines against HIV. J. Acq. Immune Defic. Syndromes 4: 451-459.
• 170. Clerici, M., D. R. Lucey, R. A. Zajac, R. N. Boswell, H. M. Gebel, H. Takahashi, J. A. Berzofsky, and G. M. Shearer. 1991. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J. Immunol. 146: 2214-2219.
• 171. Culver, K.W., C. Able, R. Toper, S. Freeman, J. A. Berzofsky, and R. M. Blaese. 1990. Lymphocytes as vehicles for gene therapy. In Cellular Immunity and the Immunotherapy of Cancer. M.T. Lotze and O.J. Finn, editors. Wiley-Liss, Inc., New York. 129-137.
• 172. Clerici, M., C. O. Tacket, C. S. Via, D. R. Lucey, S. C. Muluk, R. A. Zajac, R. N. Boswell, J. A. Berzofsky, and G. M. Shearer. 1991. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. Eur. J. Immunol. 21: 1345-1349.
• 173. Takahashi, H., T. Takeshita, B. Moreln, S. Putney, R. N. Germain, and J. A. Berzofsky. 1991. A unique subunit immunogen, ISCOM-gp160, can elicit MHC class-I-restricted HIV envelope-specific CD8+CTLs. In Vaccines 91. R.M. Chanock, H.S. Ginsberg, F. Brown, and R.A. Lerner, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. 1-7.
• 26
• 174. Lipham, W.J., T. M. Redmond, H. Takahashi, J. A. Berzofsky, B. Wiggert, G. J. Chader, and I. Gery. 1991. Recognition of peptides that are immunopathogenic but cryptic: Mechanisms that allow lymphocytes sensitized against cryptic peptides to initiate pathogenic autoimmune processes. J. Immunol. 146: 3757-3762.
• 175. Clerici, M., J. A. Berzofsky, G. M. Shearer, and C. O. Tacket. 1991. Exposure to HIV-1 indicated by HIV-specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies. J. Infect. Dis. 164: 178-182.
• 176. Berzofsky, J.A. 1991. Mechanisms of T cell recognition with application to vaccine design. Molec. Immunol. 28:217-223.
• 177. Berzofsky, J.A. 1991. Development of artificial vaccines against HIV using defined epitopes. FASEB J. 5: 2412-2418.
• 178. Berzofsky, J.A. 1991. Antigenic peptide interaction with MHC molecules: implications for the design of artificial vaccines. Seminars in Immunology 3: 203-216.
• 179. Goodman-Snitkoff, G., M. F. Good, J. A. Berzofsky, and R. J. Mannino. 1991. Role of intrastructural/intermolecular help in immunization with peptide-phospholipid complexes. J. Immunol. 147: 410-415.
• 180. Berzofsky, J.A., C. D. Pendleton, M. Clerici, J. Ahlers, D. R. Lucey, S. D. Putney, and G. M. Shearer. 1991. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T-cell responses in mice and humans of multiple MHC types. J. Clin. Invest. 88: 876-884.
• 181. Berzofsky, J.A. 1991. Human immunodeficiency virus: structural features of T-cell epitopes and their use in vaccine development. In Viruses and the Cellular Immune Response. D.B. Thomas, editor. Marcel Dekker,Inc., New York.
• 182. Berzofsky, J.A., C. D. Pendleton, M. Clerici, J. Ahlers, D. R. Lucey, S. D. Putney, and G. M. Shearer. 1991. Peptides containing multideterminant clusters of Human Immunodeficiency Virus envelope induce murine and human T -cell responses in diverse histocompatibilty types. Transac. Assoc. Amer. Phys. 104: 69-77.
• 183. Ida, H., A. Kurata, K. Eguchi, A. Kawakami, K. Migita, T. Fukuda, T. Nakamura, Y. Kusumoto, J. A. Berzofsky, and S. Nagataki. 1991. Different B-cell responses to human T-cell lymphotrophic virus type I (HTLV-I) envelope synthetic peptides in HTLV-I-infected individuals. Journal of Clinical Immunology 11:143-151.
• 184. DeGroot, A. S., M. Clerici, A. Hosmalin, S. H. Hughes, D. Barnd, C. W. Hendrix, R. A. Houghten, G. M. Shearer, and J. A. Berzofsky. 1991. Human immunodeficiency virus (HIV-1) reverse transcriptase T helper epitopes identified in mice and humans: Correlation with a cytotoxic T cell (CTL) epitope. J. Infect. Dis. 164: 1058-1065.
• 27
• 185. Takahashi, H., Y. Nakagawa, C. D. Pendleton, R. A. Houghten, K. Yokomuro, R. N. Germain, and J. A. Berzofsky. 1992. Analysis of CTL crossreactivity to an HIV-1 immunodominant determinant: elicitation of widely crossreactive CTL. In Vaccines 92. F. Brown, R. Chanock, H. Ginsberg, and R. Lerner, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. 69-74.
• 186. Shirai, M. and J. A. Berzofsky. 1992. Promiscuity of cytotoxic T-cell epitopes from the HIV-1 envelope . In Vaccines 92. F. Brown, R. Chanock, H. Ginsberg, and R. Lerner, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. 243-246.
• 187. Berzofsky, J. A. 1992. Progress towards artificial vaccines for HIV. In Vaccines 92. F. Brown, R. Chanock, H. Ginsberg, and R. Lerner, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. 41-50.
• 188. Takahashi, H., Y. Nakagawa, C. D. Pendleton, R. A. Houghten, K. Yokomuro, R. N. Germain, and J. A. Berzofsky. 1992. Induction of broadly crossreactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science , 255: 333-336.
• 189. Shirai, M., C. D. Pendleton, and J. A. Berzofsky. 1992. Broad recognition of cytotoxic T-cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules. J. Immunol. 148: 1657-1667.
• 190. Cornette, J. L., H. Margalit, C. DeLisi, and J. A. Berzofsky. 1993. The amphipathic helix as a structural feature involved in T-cell recognition. In The Amphipathic Helix. R.M. Epand, editor. CRC Press, Boca Raton., 333-346.
• 191. Clerici, M., J. V. Giorgi, C. -C. Chou, V. K. Gudeman, J. A. Zack, P. Gupta, H. -N. Ho, P. G. Nishanian, J. A. Berzofsky, and G. M. Shearer. 1992. Cell mediated immune response to human immunodeficiency virus type I (HIV-1) in seronegative homosexual men with recent sexual exposure to HIV-1. J. Infect. Dis. 165: 1012-1019.
• 192. Kozlowski, S., M. Corr, T. Takeshita, L. F. Boyd, C. D. Pendleton, R. N. Germain, J. A. Berzofsky, and D. H. Margulies. 1992. Serum angiotensin-1 converting enzyme activity processes an HIV 1 gp160 peptide for presentation by MHC class I molecules. J. Exp. Med. 175: 1417-1422.
• 193. Kullberg, M. C., E. J. Pearce, S. E. Hieny, A. Sher, and J. A. Berzofsky. 1992. Infection with Schistosoma mansoni alters Th1/Th2 cytokine responses to a non-parasite antigen. J. Immunol. 148: 3264-3270.
• 194. Sher, A., R. T. Gazzinelli, I. P. Oswald, M. Clerici, M. Kullberg, E. J. Pearce, J. A. Berzofsky, T. R. Mosmann, S. L. James, H. C. Morse, III, and G. M. Shearer. 1992. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunological Reviews 127: 183-204.
• 195. Shirai, M., T. Akatsuka, C. D. Pendleton, R. Houghten, C. Wychowski, K. Mihalik, S. Feinstone, and J. A. Berzofsky. 1992. Induction of cytotoxic T cells to a crossreactive
• 28
• epitope in the hepatitis C viral nonstructural RNA polymerase-like protein. J. Virol. 66: 4098-4106.
• 196. Clerici, M., J. A. Berzofsky, G. M. Shearer, J. V. Giorgi, and C. Tacket. 1992. On HIV-serologic testing of blood and tissue donors. New Engl. J. Med. 327: 564-565 (letter).
• 197. Quakyi, I. A., D. W. Taylor, A. H. Johnson, J. B. Allotey, J. A. Berzofsky, L. H. Miller, and M. F. Good. 1992. Development of a malaria T-cell vaccine for blood stage immunity. Scand. J. Immunol. 36 (Suppl. 11):9-16.
• 198. Hosmalin, A., S. Kumar, D. Barnd, R. Houghten, G. E. Smith, S. H. Hughes, and J. A. Berzofsky. 1992. Immunization with soluble protein-pulsed spleen cells induces class I-restricted CTL that recognize immunodominant epitopic peptides from P. falciparum and HIV-1. J. Immunol. 149: 1311-1318.
• 199. Weiss, W. R., J. A. Berzofsky, R. A. Houghten, M. Sedegah, M. Hollindale, and S. L. Hoffman. 1992. A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. J. Immunol. 149: 2103-2109.
• 200. Actor, J. K., M. Shirai, M. C. Kullberg, R. M. L. Buller, A. Sher, and J. A. Berzofsky. 1993. Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance. Proc. Natl. Acad. Sci. USA 90: 948-952.
• 201. Boehncke, W. -H., T. Takeshita, C. D. Pendleton, S. Sadegh-Nasseri, L. Racioppi, R. A. Houghten, J. A. Berzofsky, and R. N. Germain. 1993. The importance of dominant negative effects of amino acids side chain substitution in peptide-MHC molecule interactions and T cell recognition. J. Immunol. 150: 331-341.
• 202. Takahashi, H., Y. Nakagawa, M. Takeuchi, K. Yokomuro, and J. A. Berzofsky. 1993. Elicitation of CD8+ class-I-restricted CTLs by immunization with syngeneic irradiated HIV-1 envelope-derived peptide-pulsed splenic dendritic cells. In Vaccines 93. F. Brown, R.M. Chanock, H.S. Ginsberg, and R.A. Lerner, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
• 203. Berzofsky, J. A. and I. J. Berkower. 1993. Immunogenicity and antigen structure. In Fundamental Immunology. 3rd Edn. W.E. Paul, editor. Raven Press, New York., pp. 235-282.
• 204. Berzofsky, J. A., I. J. Berkower, and S. L. Epstein. 1993. Antigen-antibody interactions and monoclonal antibodies. In Fundamental Immunology. 3rd Edn. W.E. Paul, editor. Raven Press, New York. , pp. 421-465.
• 205. Berzofsky, J. A. 1995. Immunogenicity and Antigenicity. In Samter's Immunological Diseases . M.M. Frank, K.F. Austen, H.N. Claman, and E.R. Unanue, editors. Little, Brown, and Company, Boston, pp. 17-32..
• 29
• 206. Berzofsky, J. A. 1993. Epitope selection and design of synthetic vaccines: molecular approaches to enhancing immunogenicity and crossreactivity of engineered vaccines. Annals of the New York Academy of Sciences , 690: 256-264.
• 207. Ahlers, J. D., C. D. Pendleton, N. Dunlop, A. Minassian, P. L. Nara, and J. A. Berzofsky. 1993. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes following two immunizations. J. Immunol. 150: 5647-5665.
• 208. Wasserman, G. M., S. Kumar, J. Ahlers, F. Ramsdell, J. A. Berzofsky, and L. H. Miller. 1993. An approach to development of specific T lymphocyte lines using preprocessed antigens in murine malaria Plasmodium vinckei vinckei. Infect. Immun. 61: 1958-1963.
• 209. Takahashi, H., Y. Nakagawa, K. Yokomuro, and J. A. Berzofsky. 1993. Induction of CD8+ CTL by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Internat. Immunol. 5: 849-857.
• 210. Shirai, M., M. S. Vacchio, R. J. Hodes, and J. A. Berzofsky. 1993. Preferential V usage by cytotoxic T cells crossreactive between two epitopes of HIV-1 gp160 and degenerate in class I MHC restriction. J. Immunol. 151: 2283-2295.
• 211. Yanuck, M., D. P. Carbone, C. D. Pendleton, T. Tsukui, S. F. Winter, J. D. Minna, and J. A. Berzofsky. 1993. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T cells. Cancer. Res. 53: 3257-3261.
• 212. Takeshita, T., S. Kozlowski, R. D. England, R. Brower, J. Schneck, H. Takahashi, C. DeLisi, D. H. Margulies, and J. A. Berzofsky. 1993. Role of conserved regions of class I MHC molecules in the activation of CD8+ CTL by peptide and purified cell-free class I molecules. Internat. Immunol. 5: 1129-1138.
• 213. Kozlowski, S., M. Corr, M. Shirai, L. F. Boyd, C. D. Pendleton, J. A. Berzofsky, and D. H. Margulies. 1993. Multiple pathways are involved in the extracellular processing of major histocompatibility complex class I-restricted peptides. J. Immunol. 151: 4033-4044.
• 214. Williams, M. E., M. C. Kullberg, S. Barbieri, P. Caspar, J. A. Berzofsky, R. A. Seder, and A. Sher. 1993. FcR+ cells are a major source of antigen induced IL-4 in spleens of mice infected with Schistosoma mansoni . Eur. J. Immunol. 23: 1910-1916.
• 215. Shirai, M., C. D. Pendleton, J. Ahlers, T. Takeshita, M. Newman, and J. A. Berzofsky. 1994. Helper-CTL determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J. Immunol. 152: 549-556.
• 30
• 216. Clerici, M., A. V. Sison, J. A. Berzofsky, T. A. Rakusan, C. D. Brandt, M. Ellaurie, M. Villa, C. Colie, D. J. Venzon, J. L. Sever, and G. M. Shearer. 1993. Cellular immune factors associated with mother-to-infant transmission of HIV. AIDS 7:1427-1433.
• 217. Clerici, M., D. R. Lucey, J. A. Berzofsky, L. A. Pinto, T. A. Wynn, S. P. Blatt, M. J. Dolan, C. W. Hendrix, S. F. Wolf, and G. M. Shearer. 1993. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 262: 1721-1724.
• 218. Clerici, M., T. A. Wynn, J. A. Berzofsky, S. P. Blatt, C. W. Hendrix, A. Sher, R. L. Coffman, and G. M. Shearer. 1994. Role of interleukin-10 (IL-10) in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus (HIV-1). J. Clin. Invest. 93: 768-775.
• 219. Cease, K. B. and J. A. Berzofsky. 1994. Towards a vaccine for AIDS: the emergence of immunobiology-based vaccine development. Annu. Rev. Immunol. 12: 923-989.
• 220. Altuvia, Y., J. A. Berzofsky, R. Rosenfeld, and H. Margalit. 1994. Sequence features that correlate with MHC restriction . Molec. Immunol. 31: 1-19.
• 221. Berzofsky, J. A., J. D. Ahlers, M. Shirai, C. D. Pendleton, T. Takeshita, N. Dunlop, A. Minassian, M. Newman, and P. L. Nara. 1994. Construction of candidate synthetic peptide vaccines for HIV-1. In Vaccines 94: Modern approaches to new vaccines including prevention of AIDS. E. Norrby, F. Brown, R.M. Chanock, and H.S. Ginsberg, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. pp. 147-153.
• 222. Takahashi, H., T. Takeshita, S. Kozlowski, Y. Nakagawa, J. Ahlers, C. D. Pendleton, R. L. Moore, B. S. Fox, K. Yokomuro, D. H. Margulies, and J. A. Berzofsky. 1994. An immunodominant determinant of HIV-1 envelope recognized by both class-I-restricted CD8+ CTLs and class II-restricted CD4+ helper T cells shares similar MHC-binding sites. In Vaccines 94: Modern approaches to new vaccines including prevention of AIDS. E. Norrby, F. Brown, R.M. Chanock, and H.S. Ginsberg, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. pp. 181-188.
• 223. Clerici, M., J. M. Levin, H. A. Kessler, A. Harris, J. A. Berzofsky, A. L. Landay, and G. M. Shearer. 1994. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. J. Amer. Med. Assoc. 271:42-46.
• 224. Clerici, M. and J. A. Berzofsky. 1994. Cellular immunity and cytokines in HIV infection . AIDS 8: S175-S182.
• 225. Wiedenfeld, E. A., M. Fernandez-Viña, J. A. Berzofsky, and D. P. Carbone. 1994. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A *0201 peptide consensus motif . Cancer Res. 54:1175-1177.
• 226. Weissler, J. C., L. E. Rosenberg, and J. A. Berzofsky. 1994. The spring meetings: Back to the future. J. Clin. Invest. 93:457-458.
• 31
• 227. Shirai, M., H. Okada, M. Nishioka, T. Akatsuka, C. Wychowski, R. Houghten, C. D. Pendleton, S. M. Feinstone, and J. A. Berzofsky. 1994. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J. Virol. 68:3334-3342.
• 228. Kozhich, A. T., Y. -I. Kawano, C. E. Egwuagu, R. R. Caspi, R. K. Maturi, J. A. Berzofsky, and I. Gery. 1994. A pathogenic autoimmune process targeted at a surrogate epitope. J. Exp. Med. 180: 133-140.
• 229. Bermas, B. L., M. Petri, J. A. Berzofsky, A. Waisman, G. M. Shearer, and E. Mozes. 1994. Autoantibodies in mice with experimentally induced systemic lupus erythematosus (SLE) and patients with SLE bind gp120 and peptides from the HIV-1 envelope. AIDS Res. Hum. Retroviruses. 10: 1071-1077.
• 230. Berzofsky, J. A. 1994. Presidential address to the American Society for Clinical Investigation, Baltimore, Maryland, 30 April, 1994: Cross-fertilization among fields: a seminal event in the progress of biomedical research. J. Clin. Invest. 94: 911-918.
• 231. Brower, R. C., R. England, T. Takeshita, S. Kozlowski, D. H. Margulies, J. A. Berzofsky, and C. DeLisi. 1994. Minimal requirements for peptide mediated activation of CD8+ CTL. Molec. Immunol. 31: 1285-1293.
• 232. Quakyi, I. A., J. Currier, A. Fell, D. W. Taylor, T. Roberts, R. A. Houghten, R. D. England, J. A. Berzofsky, L. H. Miller, and M. F. • Good. 1994. Analysis of human T cell clones specific for conserved peptide sequences within malaria proteins: paucity of clones responsive to intact parasites. J. Immunol. 153: 2082-2092.
• 233. Nishimura, M., A. G. Kermode, M. Clerici, G. M. Shearer, J. A. Berzofsky, T. Uchiyama, S. Z. Wiktor, E. Pate, B. Maloney, A. Manns, W. Blattner, and S. Jacobson. 1994. Demonstration of human T lymphotropic virus type (HTLV-I)-specific T cell responses from seronegative and polymerase chain reaction-negative persons exposed to HTLV-I. J. Infect. Dis. 170:334-338.
• 234. Actor, J. K., M. A. Marshall, I. A. Eltoum, R. M. L. Buller, J. A. Berzofsky, and A. Sher. 1994. Increased susceptibility of mice infected with Schistosoma mansoni to recombinant vaccinia virus: association of viral persistence with egg granuloma formation. Eur. J. Immunol. 24: 3050-3056.
• 235. Meister, G. E., C. G. P. Roberts, J. A. Berzofsky, and A. S. DeGroot. 1995. Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine , 13: 581-591.
• 236. Takeshita, T., H. Takahashi, S. Kozlowski, J. D. Ahlers, C. D. Pendleton, R. L. Moore, Y. Nakagawa, K. Yokomuro, B. S. Fox, D. H. Margulies, and J. A. Berzofsky. 1995. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule. J. Immunol. 154: 1973-1986.
• 32
• 237. Berzofsky, J. A., J. D. Ahlers, M. Alexander-Miller, T. Tsukui, C. D. Pendleton, N. Dunlop, D. P. Carbone, and P. L. Nara. 1995. Developing synthetic peptide vaccines for HIV-1. In Molecular approaches to the control of infectious diseases. F. Brown, R. Chanock, H.S. Ginsberg, and E. Norrby, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, 135-142.
• 238. Berzofsky, J. A. and I. J. Berkower. 1995. Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: advances in 1994-95. AIDS 9: S143-157.
• 239. Shirai, M., T. Arichi, M. Nishioka, T. Nomura, K. Ikeda, K. Kawanishi, V. H. Engelhard, S. M. Feinstone, and J. A. Berzofsky. 1995. Cytotoxic T lymphocyte (CTL) responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J. Immunol. 154: 2733-2742.
• 240. Battegay, M., J. Fikes, A. M. Di Bisceglie, P. A. Wentworth, A. Sette, E. Celis, W. -M. Ching, A. Grakoui, C. M. Rice, K. Kurokohchi, J. A. Berzofsky, J. H. Hoofnagle, S. M. Feinstone, and T. Akatsuka. 1995. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus•-encoded peptides binding to HLA-A2.1 molecules. J. Virol. 69:2462-2470.
• 241. Berzofsky, J. A. 1995. Designing peptide vaccines to broaden recognition and enhance potency. Ann. N. Y. Acad. Sci. 754: 161-168.
• 242. Malik, A., R. Houghten, G. Corradin, S. Buus, J. A. Berzofsky, and S. L. Hoffman. 1995. Identification of a nonameric H-2Kk-restricted CD8+ cytotoxic lymphocyte epitope on the Plasmodium falciparum circumsporozoite protein. Infect. Immun. 63: 1955-1959.
• 243. Pinto, L. A., J. Sullivan, J. A. Berzofsky, M. Clerici, H. A. Kessler, A. L. Landay, and G. M. Shearer. 1995. Env-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J. Clin. Invest. 96: 867-876.
• 244. Cornette, J. L., H. Margalit, J. A. Berzofsky, and C. DeLisi. 1995. Periodic variation in side chain polarities of T cell antigenic peptides correlates with their structure and activity. Proc. Nat. Acad. Sci. USA. 92: 8368-8372.
• 245. England, R. E., M. C. Kullberg, J. L. Cornette, and J. A. Berzofsky. 1995. Molecular analysis of a heteroclitic T-cell response to the immunodominant epitope of sperm whale myoglobin: implications for peptide partial agonists. J. Immunol. 155: 4295-4306.
• 246. Shirai, M., M. Chen, T. Arichi, M. Nishioka, M. Newman, T. Nakazawa, S. M. Feinstone, and J. A. Berzofsky. 1996. Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines. J. Infect. Dis. 173: 24-31.
• 33
• 247. Shearer, G. M., M. Clerici, A. Sarin, J. A. Berzofsky, and P. A. Henkart. 1995. Cytokines in immune regulation/pathogenesis in HIV infection. Ciba Foundation Symposium 195: 142-153 (Wiley, Chichester).
• 248. Seder, R. A., K. H. Grabstein, J. A. Berzofsky, and J. F. McDyer. 1995. Cytokine interactions in human immunodeficiency virus-infected individuals: Roles of interleukin (IL)-2, IL-12, and IL-15. J. Exp. Med. 182:1067-1078.
• 249. Kurokohchi, K., T. Akatsuka, C. D. Pendleton, A. Takamizawa, M. Nishioka, M. Battegay, S. M. Feinstone, and J. A. Berzofsky. 1996. Use of recombinant protein to identify a motif-negative human CTL epitope presented by HLA-A2 in the hepatitis C virus NS3 region. J. Virol. 70: 232-240.
• 250. Takahashi, H., Y. Nakagawa, G. Leggatt, Y. Ishida, T. Saito, K. Yokomuro, and J. A. Berzofsky. 1996. Inactivation of HIV-1 envelope-specific CD8+ cytotoxic T lymphocytes by free antigenic peptide: A self-veto mechanism? J. Exp. Med. 183: 879-889.
• 251. Ahlers, J. D., N. Dunlop, C. D. Pendleton, M. Newman, P. L. Nara, and J. A. Berzofsky. 1996. Candidate HIV-1 multideterminant cluster peptide-P18MN vaccine constructs elicit Th1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization. AIDS Res. Hum. Retroviruses 12: 259-272.
• 252. Kurokohchi, K., M. Carrington, D. L. Mann, T. B. Simonis, S. M. Feinstone, T. Akatsuka, and J. A. Berzofsky. 1996. Expression of HLA class I molecules and the transporter associated with antigen processing (TAP) in hepatocellular carcinoma. Hepatology 23: 1181-1188.
• 253. Kullberg, M. C., J. A. Berzofsky, D. Lj. Jankovic, S. Barbieri, M. E. Williams, P. Perlmann, A. Sher, and M. Troye-Blomberg. 1996. T-cell-derived IL-3 induces the production of IL-4 by non-B, non-T cells to amplify the Th2-cytokine response to a non-parasite antigen in Schistosoma mansoni-infected mice. J. Immunol. 156: 1482-1489.
• 254. Quakyi, I. A., L. H. Miller, M. F. Good, J. D. Ahlers, S. N. Isaacs, J. H. Nunberg, R. A. Houghten, D. B. Keister, J. E. Coligan, B. Moss, D. Alling, J. A. Berzofsky, and D. C. Kaslow. 1995. Synthetic Peptides from P. falciparum sexual stage 25-kDa protein induce antibodies that react with the native protein: the role of IL-2 and conformational structure on immunogenicity of Pfs25. Peptide Research 8: 335-344.
• 255. Ciernik, I. F., J. A. Berzofsky, and D. P. Carbone. 1995. Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53. Hybridoma 14:139-142.
• 256. Alexander-Miller, M. A., K. C. Parker, T. Tsukui, C. D. Pendleton, J. E. Coligan, and J. A. Berzofsky. 1996. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-1 envelope protein to human CTL. Int. Immunol. 8: 641-649.
• 34
• 257. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 93: 4102-4107.
• 258. Roberts, C. G. P., G. E. Meister, B. T. Jesdale, J. Lieberman, J. A. Berzofsky, and A. S. DeGroot. 1996. Prediction of HIV peptide epitopes by a novel algorithm. AIDS Res. Hum. Retroviruses 12: 593-610.
• 259. Landay, A. L., M. Clerici, F. Hashemi, H. Kessler, J. A. Berzofsky, and G. M. Shearer. 1996. In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J. Infect. Dis. 173: 1085-1091.
• 260. Ciernik, I. F., J. A. Berzofsky, and D. P. Carbone. 1996. Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope, and are lysed by mutant-specific CTL. Clin. Cancer. Res. 2: 877-882..
• 261. Ciernik, I. F., J. A. Berzofsky, and D. P. Carbone. 1996. Induction of cytotoxic T lymphocytes and anti-tumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol. 156: 2369-2375.
• 262. Gabrilovich, D. I., S. Nadaf, J. Corak, J. A. Berzofsky, and D. P. Carbone. 1996. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors.. Cellular Immunol. 170: 111-119.
• 263. Clerici, M., A. Sarin, J. A. Berzofsky, A. L. Landay, H. A. Kessler, F. Hashemi, C. W. Hendrix, S. P. Blatt, J. Rusnak, M. J. Dolan, R. L. Coffman, P. A. Henkart, and G. M. Shearer. 1996. Antigen-stimulated apoptotic T cell death in HIV infection is selective for CD4+ T cells, modulated by cytokines and effected by lymphotoxin. AIDS 10: 603-611.
• 264. Tian, J. -H., L. H. Miller, D. C. Kaslow, J. Ahlers, M. F. Good, D. W. Alling, J. A. Berzofsky, and S. Kumar. 1996. Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine. J. Immunol. 157: 1176-1183.
• 265. Alexander-Miller, M. A., G. R. Leggatt, A. Sarin, and J. A. Berzofsky. 1996. Role of antigen, CD8, and CTL avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184: 485-492.
• 266. Tsukui, T., A. Hildesheim, M. H. Schiffman, J. Lucci III, D. Contois, P. Lawler, B. B. Rush, A. T. Lorincz, A. Corrigan, R. D. Burk, W. Qu, M. A. Marshall, D. Mann, M. Carrington, M. Clerici, G. M. Shearer, D. P. Carbone, D. R. Scott, R. A. Houghten, and J. A. Berzofsky. 1996. IL-2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res. 56: 3967-3974.
• 35
• 267. Huang, X., M. C. Smith, J. A. Berzofsky, and J. J. Jr. Barchi. 1996. Structural comparison of a 15-residue peptide from the V3 loop of HIV-1IIIB and an O-glycosylated analogue. FEBS Letters 393: 280-286.
• 268. Shirai, M., K. Kurokohchi, C. D. Pendleton, T. Arichi, L. F. Boyd, H. Takahashi, D. H. Margulies, and J. A. Berzofsky. 1996. Reciprocal CTL cross-reactivity interactions between two major epitopes within HIV-1 gp160. J. Immunol. , 157: 4399-4411.
• 269. Beretta, A., S. H. Weiss, G. Rappocciolo, R. Mayur, D. De Santis, J. Quirinale, A. Cosma, P. Robbioni, G. M. Shearer, J. A. Berzofsky, M. L. Villa, A. Siccardi, and M. Clerici. 1996. Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope. J. Infect. Dis. 173: 472-476.
• 270. Pinto, L. A., A. L. Landay, J. A. Berzofsky, H. A. Kessler, and G. M. Shearer. 1997. Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. Am. J. Med. 102 (5B): 21-24.
• 271. Leggatt, G. R., M. A. Alexander-Miller, A. Kumar (née Malik), S. L. Hoffman, and J. A. Berzofsky. 1997. Cytotoxic T lymphocyte (CTL) adherence assay (CAA): A non-radioactive assay for murine CTL recognition of peptide-MHC class I complexes. J. Immunol. Methods, 201: 1-10.
• 272. Sarin, A., M. S. Williams, M. A. Alexander-Miller, J. A. Berzofsky, C. M. Zacharchuk, and P. A. Henkart. 1997. Target cell lysis by CTL granule exocytosis is independent of ICE/Ced-3 family proteases. Immunity 6: 209-215.
• 273. Saito, T., G. J. Sherman, K. Kurokohchi, Z. -P. Guo, M. Donets, M. -Y. W. Yu, J. A. Berzofsky, T. Akatsuka, and S. M. Feinstone. 1997. Plasmid DNA-based immunization for hepatitis C virus structural proteins, immune responses in mice. Gastroenterology 112: 1321-1330.
• 274. Shirai, M., S. Kozlowski, D. H. Margulies, and J. A. Berzofsky. 1997. Degenerate MHC restriction reveals the contribution of class I MHC molecules in determining the fine specificity of CTL recognition of an immunodominant determinant of HIV-1 gp160 V3 loop. J. Immunol. 158: 3181-3188.
• 275. Ahlers, J. D., N. Dunlop, D. W. Alling, P. L. Nara, and J. A. Berzofsky. 1997. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: GM-CSF and TNF synergize with IL-12 to enhance induction of CTL. J. Immunol. 158: 3947-3958.
• 276. Kozhich, A. T., R. R. Caspi, J. A. Berzofsky, and I. Gery. 1997. Immunogenicity and immunopathogenicity of an autoimmune epitope are potentiated by increasing MHC binding through residue substitution. J. Immunol. 158: 4145-4151.
• 36
• 277. Zhang, C., J. L. Cornette, J. A. Berzofsky, and C. DeLisi. 1997. The organization of human leukocyte antigen class I epitopes in HIV genome products: Implications for HIV evolution and vaccine design. Vaccine 15: 1291-1302.
• 278. Smith, M. C., C. D. Pendleton, V. E. Maher, M. J. Kelley, D. P. Carbone, and J. A. Berzofsky. 1997. Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular processing. Internat. Immunol. 9: 1085-1093.
• 279. Goletz, T. J., K. R. Klimpel, S. H. Leppla, J. M. Keith, and J. A. Berzofsky. 1997. Delivery of antigens to the MHC class I pathway using bacterial toxins. Hum. Immunol. 54: 129-136..
• 280. DeGroot, A. S., B. M. Jesdale, and J. A. Berzofsky. 1998. Prediction and determination of MHC ligands and T cell epitopes. In Immunological Methods in Microbiology Vol. 25. Immunology of Infection. S.H.E. Kaufmann and D. Kabelitz, editors. Academic Press, London, Chap. 3, pp. 79-106.
• 281. Hirunpetcharat, C., J. -H. Tian, D. C. Kaslow, N. van Rooijen, S. Kumar, J. A. Berzofsky, L. H. Miller, and M. F. Good. 1997. Complete protective immunity induced in mice by immunization with the 19kDa carboxyterminal fragment of the merozoite surface protein-1 (MSP119) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: Correlation of protection with antigen-specific antibody titer, but not effector CD4+ T cells. J. Immunol. 159: 3400-3411.
• 282. DeGroot, A. S., G. E. Meister, J. L. Cornette, H. Margalit, C. DeLisi, and J. A. Berzofsky. 1997. Computer prediction of T-cell epitopes. In New Generation Vaccines. M.M. Levine, G.C. Woodrow, J.B. Kaper, and G.S. Cobon, editors. Marcel Dekker, Inc., New York. 127-138.
• 283. Ahlers, J. D., T. Takeshita, C. D. Pendleton, and J. A. Berzofsky. 1997. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc. Natl. Acad. Sci. U. S. A. 94: 10856-10861.
• 284. Shirai, M., T. Arichi, T. Nakazawa, and J. A. Berzofsky. 1998. Persistent infection by Helicobacter pylori downmodulates virus-specific CD8+ cytotoxic T cell response and prolongs viral infection. J. Infect. Dis. 177: 72-80.
• 285. Goletz, T.J., K. R. Klimpel, N. Arora, S. H. Leppla, J. M. Keith, and J. A. Berzofsky. 1997. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Proc. Natl. Acad. Sci. U.S.A. 94: 12059-12064.
• 286. Belyakov, I. M., M. A. Derby, J. D. Ahlers, B. L. Kelsall, P. Earl, B. Moss, W. Strober, and J. A. Berzofsky. 1998. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. 95:1709-1714.
• 37
• 287. Hildesheim, A., M. H. Schiffman, T. Tsukui, C. A. Swanson, J. Lucci, D. R. Scott, A. G. Glass, B. B. Rush, A. T. Lorincz, A. Corrigan, R. D. Burk, K. Helgesen, R. A. Houghten, M. E. Sherman, R. J. Kurman, J. A. Berzofsky, and T. R. Kramer. 1997. Immune activation in cervical neoplasia: Cross-sectional association between plasma soluble interleukin 2 receptor levels and disease. Cancer Epidemiol. Biomark. Preven. 6:807-813.
• 288. Leggatt, G. R. and J. A. Berzofsky. 1999. Cytotoxic T cell adherence assay (CAA). In Methods in Molecular Biology Series : T cell protocols. K. Kearse, editor. Humana Press, Totowa, NJ.,134: 277-281.
• 289. Belyakov, I. M., L. S. Wyatt, J. D. Ahlers, P. Earl, C. D. Pendleton, B. L. Kelsall, W. Strober, B. Moss, and J. A. Berzofsky. 1998. Induction of mucosal CTL response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing HIV 89.6 envelope protein. J. Virol. 72: 8264-8272.
• 290. Leggatt, G. R., A. Hosmalin, C. D. Pendleton, A. Kumar, S. Hoffman, and J. A. Berzofsky. 1998. The importance of pairwise interactions between peptide residues in the delineation of T cell receptor specificity. J Immunol. 161: 4728-4735:
• 291. Sarobe, P., C. D. Pendleton, T. Akatsuka, D. Lau, V. H. Engelhard, S. M. Feinstone, and J. A. Berzofsky. 1998. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J. Clin. Invest. 102: 1239-1248.
• 292. Alexander-Miller, M. A., M. A. Derby, A. Sarin, P. A. Henkart, and J. A. Berzofsky. 1998. Supra-optimal peptide/MHC causes a decrease in Bcl-2 and allows TNF- •receptor II-mediated apoptosis of CTL. J. Exp. Med. 188: 1391-1399.
• 293. Berzofsky, J. A., I. J. Berkower, and S. L. Epstein. 1999. Antigen-antibody interactions and monoclonal antibodies. In Fundamental Immunology. W.E. Paul, editor. Lippincott-Raven, Philadelphia. 75-110.
• 294. Berzofsky, J. A. and I. J. Berkower. 1999. Immunogenicity and antigen structure. In Fundamental Immunology. W.E. Paul, editor. Lippincott-Raven, Philadelphia. 651-699.
• 295. Goletz, T. J., C. L. Mackall, J. A. Berzofsky, and L. J. Helman. 1998. Molecular alterations in pediatric sarcomas: potential targets for immunotherapy. Sarcoma 2:77-87.
• 296. Tian, J.-H., M. F. Good, C. Hirunpetcharat, S. Kumar, I. T. Ling, D. Jackson, J. Cooper, J. Lukszo, J. Coligan, J. Ahlers, A. Saul, J. A. Berzofsky, A. A. Holder, L. H. Miller, and D. C. Kaslow. 1998. Definition of T cell epitopes within the 19kDa carboxyterminal fragment Plasmodium yoelii merozoite surface protein 1 (MSP119) and their role in immunity malaria. Parasite Immunol. 20: 263-278.
• 297. Shirai, M., T. Arichi, M. Chen, M. Nishioka, K. Ikeda, H. Takahashi, N. Enomoto, T. Saito, M. E. Major, T. Nakazawa, T. Akatsuka, S. M. Feinstone, and J. A. Berzofsky. 1999. T
• 38
• cell recognition of hypervariable region 1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: Preferential help for induction of antibodies to the hypervariable region.. J. Immunol. 162: 568-576.
• 298. Oscherwitz, J., F. M. Gotch, K. B. Cease, and J. A. Berzofsky. 1999. New insights and approaches regarding B and T cell epitopes in HIV vaccine design. AIDS , 13 (Suppl. A): S163-S174.
• 299. Suh, W-K., M. A. Derby, M. F. Cohen-Doyle, G. J. Schoenhals, K. Früh, J. A. Berzofsky, and D. B. Williams. 1999. Interaction of murine MHC class I molecules with tapasin and TAP enhances peptide loading and involves the heavy chain 3 domain. J. Immunol. 162: 1530-1540.
• 300. Belyakov, I. M., J. D. Ahlers, B. Y. Brandwein, P. Earl, B. L. Kelsall, B. Moss, W. Strober, and J. A. Berzofsky. 1998. The importance of local mucosal HIV-specific CD8+ cytotoxic T lymphocytes for resistance to mucosal-viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Invest. 102: 2072-2081.
• 301. D'Amico, R., L. A. Pinto, P. Meyer, A. L. Landay, A. A. Harris, M. Clerici, J. A. Berzofsky, G. M. Shearer, and H. A. Kessler. 1999. Effect of zidovudine postexposure prophylaxis on the department of HIV-specific cytotoxic T-lymphocyte responses in HIV-exposed health care workers. Infection Control and Hospital Epidemiology , 20: 428-430.
• 302. McDyer, J. F., M. Dybul, T. J. Goletz, A. L. Kinter, E. K. Thomas, J. A. Berzofsky, A. S. Fauci, and R. A. Seder. 1999. Differential effects of CD40 ligand/trimer stimulation on the ability of dendritic cells to replicate and transmit HIV infection: Evidence for CC-chemokine-dependent and -independent mechanisms. J. Immunol. , 162: 3711-3717.
• 303. Belyakov, I. M., B. Moss, W. Strober, and J. A. Berzofsky. 1999. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. U. S. A. 96: 4512-4517.
• 304. Berzofsky, J. A., J. D. Ahlers, M. A. Derby, C. D. Pendleton, T. Arichi, and I. M. Belyakov. 1999. Approaches to improve engineered vaccines for HIV and other viruses that cause chronic infections. Immunological Reviews 170: 151-172.
• 305. Matsui, S., J. D. Ahlers, A. O. Vortmeyer, M. Terabe, T. Tsukui, D. P. Carbone, L. A. Liotta, and J. Berzofsky. 1999. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4+ T cells through an effect on quality of CTL. J. Immunol. 163: 184-193.
• 306. Maher, V. E., B. S. Worley, D. Contois, M. C. Smith, M. J. Kelley, M. Stipanov, S. N. Khleif, T. Goletz, L. van den Broeke, C. Mackall, L. J. Helman, D. P. Carbone, and J. A. Berzofsky. 2000. Mutant oncogene and tumor suppressor gene products and fusion
• 39
• proteins created by chromosomal translocations as targets for cancer vaccines. In Peptide-based cancer vaccines. W.M. Kast, editor. Landes Bioscience, Austin, pp. 17-39.
• 307. Chung, D. H., J. Dorfman, D. Plaksin, K. Natarajan, I. M. Belyakov, R. Hunziker, J. A. Berzofsky, W. M. Yokoyama, M. G. Mage, and D. H. Margulies. 1999. Natural killer (NK) and cytolytic T lymphocyte (CTL) recognition of a single chain H-2Dd molecule: distinct sites of H-2Dd interact with NK and T cell receptors. J. Immunol. 163: 3699-3708.
• 40
• 308. Pinto, L. A., J. A. Berzofsky, K. R. Fowke, R. F. Littles, F. Merced-Galindez, R. Humphreys, J. Ahlers, N. Dunlop, R. B. Cohen, S. M. Steinberg, P. Nara, G. M. Shearer, and R. Yarchoan. 1999. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS 13: 2003-2012.
• 309. Berzofsky, J. A., L. J. Helman, and D. P. Carbone. 2000. Oncogene products and mutated proteins as tumor antigens. In Biologic Therapy of Cancer: Principles and Practice (3rd Ed.). S. A. Rosenberg, editor. Lippincott Williams & Wilkins, Philadelphia, 526-540.
• 310. Arichi, T., T. Saito, M. E. Major, I. M. Belyakov, M. Shirai, V. H. Engelhard, S. M. Feinstone, and J. A. Berzofsky. 2000. Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV specific CTL induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model. Proc. Natl. Acad. Sci. U.S.A. 97: 297-302. (Retracted due to discovery of fraud by first author.)
• 311. Ciernik, I. F., P. Romero, J. A. Berzofsky, and D. P. Carbone. 1999. Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope. Int. J. Rad. Oncolo. Biol. Phys. 45:735-741.
• 312. Parra, M., G. Hui, A. Johnson, J. A. Berzofsky, T. Roberts, I. A. Quakyi, and D. W. Taylor. 2000. Characterization of conserved T and B cell epitopes in Plasmodium falciparum major merozoite surface protein-1 (MSP-1). Infect. Immun. 68: 2685-2691.
• 313. Berzofsky, J. A. 2000. Immunogenicity and Antigenicity. In Samter's Immunologic Diseases Sixth Edition. K.F. Austen, M.M. Frank, J.P. Atkinson, and H. Cantor, editors. Lippincott Williams & Wilkins, Baltimore, Chap. 7, pp. 65-82.
• 314. Berzofsky J.A., J.D. Ahlers, I.M. Belyakov. 2002. Design of Engineered Vaccines for HIV. In: Wong-Staal F, Gallo RC, editors. AIDS Vaccine Research. New York: Marcel Dekker, Inc. 173-206..
• 315. Nakagawa Y, T. Takeshita, J.A. Berzofsky, H. Takahashi. 2000. Analysis of mechanism for extracellular processing in the presentation of HIV-1 envelope protein derived peptide to epitope-specific CTL. Immunology. 101: 76-82..
• 316. Grene E, D.A. Newton, E.A. Brown, J.A. Berzofsky, S. Gattoni-Celli, G.M. Shearer. 2000. Semi-allogeneic cell hybrids stimulate HIV-1 envelope-specific cytotoxic T lymphocytes. AIDS: 14: 1497-1506.
• 317. Polakova, K., D. Plaksin, D.H. Chung, I.M. Belyakov, J.A. Berzofsky, and D.H. Margulies, 2000. Antibodies directed against the MHC-I molecule H-2Dd complexed with an antigenic peptide: similarities to a T cell receptor with the same specificity. J. Immunol. 165: 5703-5712.
• 41
• 318. Belyakov, I.M., J.D. Ahlers, J.D. Clements, W. Strober, and J.A. Berzofsky, 2000. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific cytotoxic T lymphocytes. J. Immunol. 165: 6454-6462.
• 319. Terabe, M., S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D. D. Donaldson, D. P. Carbone, W. E. Paul, and J. A. Berzofsky. 2000. NKT cell-mediated repression of tumour immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunology 1: 515-520.
• 320. Takahashi, M., Y. Nakagawa, J. A. Berzofsky, and H. Takahashi. 2001. Counter-regulation of cytolytic activity and cytokine production in human immunodeficiency virus (HIV)-1-specific murine CD8+ cytotoxic T lymphocytes by free antigenic peptide. Int Immunol. 13: 43-51.
• 321. Mackall, C., J. Berzofsky, and L. J. Helman. 2000. Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. Clin. Orthopaedics and Related Research 373: 25-31.
• 322. Derby, M. A., M. A. Alexander-Miller, R. Tse, and J. A. Berzofsky. 2001. High avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low avidity CTL. J. Immunol., 166: 1690-1697.
• 323. Shirai, M., R. Fujinaga, T. Masaki, and J. A. Berzofsky. 2001. Impaired development of HIV-1 gp160-specific CD8+ cytotoxic T cells by a delayed switch from Th1 to Th2 cytokine phenotype in mice with Helicobacter pylori infection. Eur. J. Immunol., 31: 516-526.
• 324. Simon, R. M., S. M. Steinberg, M. Hamilton, A. Hildesheim, S. Khleif, L. W. Kwak, C. L. Mackall, J. Schlom, S. L. Topalian, and J. A. Berzofsky. 2001. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J. Clin. Oncol. 19: 1848-1854.
• 325. McGettigan, J. P., H. D. Foley, I. M. Belyakov, J. A. Berzofsky, R. J. Pomerantz, and M. J. Schnell. 2001. Rabies virus-based vectors expressing HIV-1 envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelop proteins from different HIV-1 isolates. J. Virol. 75: 4430-4434.
• 326. Derby, M.A., J. Wang, D. H. Margulies, and J. A. Berzofsky. 2001. Two intermediate avidity CTL clones with a disparity between functional avidity and MHC tetramer staining. Internat. Immunol. 13: 817-824.
• 327. Ahlers, J. D., I. M. Belyakov, S. Matsui, and J. A. Berzofsky. 2001. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Internat. Immunol.13: 897-908.
• 328. Wong, E. C. C., V. E. Maher, K. Hines, J. Lee, C. S. Carter, T. Goletz, W. Kopp, C. L. Mackall, J. A. Berzofsky, and E. J. Read. 2001. Development of a clinical-scale method for generation of dendritic cells from peripheral blood monocytes for use in cancer immunotherapy. Cytotherapy 3: 19-29.
• 42
• 329. Chung, D. H., I. M. Belyakov, M. A. Derby, J. Wang, L. F. Boyd, J. A. Berzofsky, and D. H. Margulies. 2001. Competitive inhibition in vivo and skewing of the T cell repertoire of antigen-specific CTL priming by an anti-peptide-MHC mAb. J. Immunol. 167: 699-707.
• 330. Horner, A. A., S. K. Datta, K. Takabayashi, I. M. Belyakov, T. Hayashi, N. Cinman, M.-D. Nguyen, J. H. Van Uden, J. A Berzofsky, D D. Richman, and E. Raz. 2001. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J. Immunol.,167: 1584-1591.
• 331. Ahlers, J. D., I. M. Belyakov, S. Matsui, and J. A. Berzofsky. 2001. Signals delivered through TCR instruct IL-12R expression: IL-12 and TNF synergize for IL-12R expression at low antigen dose. Internat. Immunol. 13: 1433-1442.
• 332. Derby, M. A., J. T. Snyder, R. Tse, M. A. Alexander-Miller, and J. A. Berzofsky. 2001. An abrupt and concordant initiation of apoptosis: antigen-dependent death of CD8+ CTL. Eur. J. Immunol. 31: 2951-2959.
• 333. Worley, B. S., L. T. van den Broeke, T. J. Goletz, C. D. Pendleton, E. M. Daschbach, E. K. Thomas, F. M. Marincola, L. J. Helman, and J. A. Berzofsky. 2001. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Research 61: 6868-6875.
• 334. Hel, Z., J. Nacsa, B. Kelsall, W.-P. Tsai, N. Letvin, R. W. Parks, E. Tryniszewska, L. Picker, M. G. Lewis, Y. Edghill-Smith, M. Moniuszko, R. Pal, L. Stevceva, J. D. Altman, T. M. Allen, D. Watkins, J. V. Torres, J. A. Berzofsky, I. M. Belyakov, W. Strober, and G. Franchini. 2001. Impairment of gag-specific CD8+ T-cell function in mucosal and systemic compartments of SIVmac251- and SHIVku2- infected macaques. J. Virol., 75: 11483-11495.
• 335. Marshall, M. A., D. Jankovic, V. E. Maher, A. Sher, and J. A. Berzofsky. 2001. Mice infected with Schistosoma mansoni develop a novel non-T lymphocyte suppressor population which inhibits virus-specific CTL induction via a soluble factor. Microbes and Infection 3: 1051-1061.
• 336. Belyakov, I. M., J. Wang , R. Koka, J. D. Ahlers, J. T. Snyder, R. Tse , J. Cox , J. S. Gibbs, D. H. Margulies and J. A. Berzofsky. 2001. Activating CTL precursors to reveal CTL function without skewing the repertoire by in vitro expansion. Eur. J. Immunol. 31: 3557-3566.
• 337. Berzofsky, J. A. 2001. Design of engineered vaccines for systemic and mucosal immunity to HIV. Pathol. Biol. 49: 466-467.
• 338. Dagher, R., L. Long, E.J. Read, S.F. Leitman, C.S. Carter, M. Tsokos, S. Kumar, T.J. Goletz, J.A. Berzofsky, L.J. Helman and C.L. Mackall. 2002. A pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing's sarcoma and alveolar rhabdomyosarcoma: an interinstitute NIH study. Medical and Pediatric Oncology, 38: 158-164.
• 43
• 339. Bukreyev, A., I. M. Belyakov, J. A. Berzofsky, B. R. Murphy, and P. L. Collins. 2001. Granulocyte-macrophage colony-stimulating factor expressed by a recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. J. Virol., 75: 12128-12140.
• 340. Ahlers, J.D., I. M. Belyakov, E. K. Thomas, and J. A. Berzofsky. 2001. High affinity T-helper epitope induces complementary helper and APC polarization, increased CTL and protection against viral infection. J. Clin. Invest. 108: 1677-1685.
• 341. Belyakov, I. M., Z. Hel, B. Kelsall, V. A. Kuznetsov, J. D.Ahlers, J. Nacsa, D. I. Watkins, T. M. Allen, A. Sette, J. Altman , R. Woodward , P. D. Markham , J. D. Clements , G. Franchini, W. Strober and J. A. Berzofsky. 2001. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nature Medicine 7: 1320-1326.
• 342. Berzofsky, J. A., J. D. Ahlers, and I. M. Belyakov. 2001. Strategies for designing and optimizing new generation vaccines. Nature Reviews Immunology 1: 209-219.
• 343. De Groot, A. S., H. Sbai, W. Martin, and J. A. Berzofsky. 2003. Use of bioinformatics to predict MHC ligands and T-cell epitopes: Application to epitope-driven vaccine design. In S. H. E. Kaufmann and D. Kabelitz, editors. Methods in Microbiology: Immunology of Infection, 2nd Edition. London: Academic Press. In press.
• 344. Biragyn, A., I. M. Belyakov, Y. H. Chow, D. S. Dimitrov, J. A. Berzofsky, and L. W. Kwak. 2002. DNA vaccines encoding HIV-1 gp120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood, 100: 1153-1159.
• 345. Mackall, C. L., T. J. Goletz, J. A. Berzofsky, and L. J. Helman. 2002. Toward new approaches: targeting tumor specific molecular alterations with immune based therapy. In C. S. Cooper, editor, Translocations in Solid Tumors. Georgetown, TX: Landes Bioscience. In press.
• 346. Ahlers, J. D., I. M. Belyakov, M. Terabe, R. Koka, D. D. Donaldson, E. K. Thomas, and J. A. Berzofsky. 2002. A push-pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with GM-CSF and CD40L. Proc. Natl. Acad. Sci. USA 99: 13020-13025.
• 347. Allen, T.M., P. Jing, B. Calore, H. Horton, D.H. O'Connor, T. Hanke, M. Piekarczyk, R. Ruddersdorf, B.R. Mothe, C. Emerson, N. Wilson, J.D. Lifson, I.M. Belyakov, J.A. Berzofsky, C. Wang, D.B. Allison, D.C. Montefiori, R.C. Desrosiers, S. Wolinsky, K.J. Kunstman, J.D. Altman, A. Sette, A.J. McMichael, and D.I. Watkins. 2002. Effects of Cytotoxic T Lymphocytes (CTL) Directed against a Single Simian Immunodeficiency Virus (SIV) Gag CTL Epitope on the Course of SIVmac239 Infection. J Virol 76:10507-10511.
• 348. Ostrand-Rosenberg, S., V.K. Clements, M. Terabe, J.M. Park, J. Berzofsky, and S.K. Dissanayake. 2002. Resistance to metastatic disease in Stat6-deficient mice requires
• 44
• hematopoietic and non-hematopoietic cells and is IFN-dependent. J. Immunol. 169: 5796-5804.
• 349. Berzofsky, J. A., J. D. Ahlers, M. Terabe, and I. M. Belyakov. 2003. Enhancing mucosal and systemic T cell responses and efficacy of HIV/SIV vaccines. In, M. Vicari, B. Dodet, and M. Girard eds., Retroviruses of Human AIDS and Related Animal Diseases: Proceedings of the XIIIth Cent Gardes Symposium, Elsevier: Paris, pp. 89-93.
• 350. Oh, S., J.W. Hodge, J.D. Ahlers, , D.S. Burke, J. Schlom, and J.A. Berzofsky, 2003. Selective induction of high avidity CTL by altering the balance of signals from antigen presenting cells. J Immunol. 170: 2523-2530.
• 351. Takahashi, M., E. Osono, Y. Nakagawa, J. Wang, J. Berzofsky, D.H. Margulies, and H. Takahashi. 2002. Rapid induction of apoptosis in CD8+ HIV-1 envelope-specific murine CTLs by short exposure to antigenic peptide. J Immunol 169:6588-6593.
• 352. Oh, S., J. A. Berzofsky, D. S. Burke, T. A. Waldmann, and L. P. Perera. 2003. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc. Natl. Acad. Sci. USA 100: 3392-3397.
• 353. Pinto, L.A., J. Edwards, P.E. Castle, C.D. Harro, D.R. Lowy, J.T. Schiller, D. Wallace, W. Kopp, J.W. Adelsberger, M.W. Baseler, J.A. Berzofsky, and A. Hildesheim. 2003. Cellular immune responses to HPV-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J. Infec. Diseases, 188: 327-338.
• 354. Ahlers, J.D., I.M. Belyakov, and J.A. Berzofsky. 2003. Cytokine, chemokine and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Current Molecular Medicine 3:85-94.
• 355. Snyder, J.T., M. A. Alexander-Miller, J. A. Berzofsky, and I. M. Belyakov. 2003. Molecular mechanisms and biological significance of CTL avidity. Current HIV Research 1: 287-294.
• 356. Belyakov, I.M., P. Earl, A. Dzutsev, V.A. Kuznetsov, M. Lemon, L.S. Wyatt, J.T. Snyder, J.D. Ahlers, G. Franchini, B. Moss, and J.A. Berzofsky. 2003. Shared modes of protection against poxivirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A.100: 9458-9463.
• 357. Okazaki, T., D.C. Pendleton, F. Lemonnier, and J.A. Berzofsky. 2003. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen. J. Immunol. 171: 2548-2555.
• 358. Enghill-Smith, Y., D. Venzon, T. Karpova, J. McNally, J. Nacsa, W.-P. Tsai, E. Tryniszewska, M. Moniuszko, S.J. Snodgrass, J. Parrish, M.G. Lewis, J.A. Berzofsky, I.M. Belyakov, B. Moss, J. Tartaglia, M. Bray, V. Hirsh, H. Golding, and G. Franchini. 2003. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J. Infec. Dis.188: 1181-1191.
• 45
• 359. Terabe, M., J.M. Park, and B. J.A. 2004. Role of IL-13 in negative regulation of anti-tumor immunity. Cancer Immunol and Immunotherapy, 53: 79-85.
• 360. Terabe, M., S. Matsui, J.-M. Park, M. Mamura, N. Noben-Trauth, D.D. Donaldson, W. Chen, S.M. Wahl, S. Ledbetter, B. Pratt, J.J. Letterio, W.E. Paul, and J.A. Berzofsky. 2003. Transforming Growth Factor- production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med , 198: 1741-1752.
• 361. van den Broeke, L.T., E.M. Daschbach, E.K. Thomas, G. Andringa, and B. J.A. 2003. Dendritic cell induced activation of adaptive and innate antitumor immunity. J Immunol., 171: 5842-5852.
• 362. Terabe, M., and Berzofsky, J.A. 2004. Immunoregulatory T cells in tumor immunity. Current Opinion in Immunology 16: 157-162.
• 363. Belyakov, I.M., and J.A. Berzofsky. 2004. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 20: 247-253.
• 364. Belyakov, I.M., S.A. Hammond, J.D. Ahlers, G.M. Glenn, and J.A. Berzofsky. 2004. Transcutaneous immunization induces mucosal CTL and protective immunity by migration of primed skin dendritic cells. Journal of Clinical Investigation 113: 998-1007.
• 365. Oh, S., M. Terabe, C.D. Pendleton, A. Bhattacharyy, T.K. Bera, M. Epel, Y. Reiter, J. Phillips, W.M. Linehan, C. Kasten-Sportes, I. Pastan, and J.A. Berzofsky. 2004. Human CTL to wild type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Research 64: 2610-2618.
• 366. Berzofsky, J.A., I.J. Berkower, and S.L. Epstein. 2003. Antigen-antibody interactions and monoclonal antibodies. In Fundamental Immunology. W.E. Paul, editor. Lippincott Williams & Wilkins, Philadelphia. 69-105.
• 367. Berzofsky, J.A., and I.J. Berkower. 2003. Immunogenicity and antigen structure. In Fundamental Immunology. W.E. Paul, editor. Lippincott Williams & Wilkins, Philadelphia. 631-683.
• 368. Lee, W.J., K.P. Cantor, J.A. Berzofsky, S.H. Zahm, and A. Blair. 2004. Non-hodgkin's lymphoma among asthmatics exposed to pesticides. Internat. J. Cancer 111: 298-302.
• 369. Snyder, J.T., I.M. Belyakov, A. Dzutsev, F. Lemonnier, and J.A. Berzofsky. 2004. Protection against lethal virus challenge in HLA-A2 transgenic mice by peptide immunization with an HLA-A0201 restricted CD8+ T cell epitope of vaccinia and variola. Journal of Virology 78: 7052-7060.
• 46
• 370. Berzofsky, J.A. 2004.New strategies for designing and optimizing vaccines. American Society for Microbiology News 70 (5): 219-223.
• 371. Berzofsky, J.A., and I.M. Belyakov. 2004. Mucosal vaccines to induce cellular immunity against HIV and other viral infections. In Vaccines. C.A. de Quadros, editor. Pan American Health Organization, Washington, DC. 223-237.
• 372. Berzofsky, J.A., M. Terabe, S. Oh, I. M. Belyakov, J. D. Ahlers, J. E. Janik, and J. C. Morris. 2004. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113: 1515-1525.
• 373. Kuznetsov, V.A., Stepanov, J.A. Berzofsky, and I.M. Belyakov. 2004. Assessment of the relative therapeutic effects of vaccines on virus load and immune responses in small groups at several time points: An efficacy of mucosal and subcutaneous polypeptide vaccines in rhesus macaques exposed to SHIV. J of Clinical Virology 31S: S69-S82.
• 374. Berzofsky, J.A., J. Ahlers, J. Janik, J. Morris, S. Oh, M. Terabe, and I.M. Belyakov. 2004. Progress on new vaccine strategies against chronic viral infections. J Clin Invest 114:450-462.
• 375. Park, J.M., M. Terabe, L.T. van den Broeke, D.D. Donaldson, and J.A. Berzofsky. 2005. Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. Internat. J. Cancer 114: 80-87. (Pub on line Oct. 2004)
• 376. Belyakov, I.M., J.D. Ahlers, and J.A. Berzofsky. 2004. Mucosal AIDS vaccines: current status and future directions. Expert Rev. Vaccines 3:Suppl. 65-73.
• 377. Sakai, Y., B.J. Morrison, J.D. Burke, J.M. Park, M. Terabe, J.E. Janik, G. Forni, J.A. Berzofsky, and J.C. Morris. 2004. Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice. Cancer Research 64: 8022-8028.
• 378. Oh, S., L.P. Perera, D.S. Burke, T.A. Waldmann, and J.A. Berzofsky. 2004. IL-15/IL-15R alpha-mediated avidity maturation of memory CD8+ T cells. Proc Natl Acad Sci U S A, 101: 15154-15159.
• 379. Pinto, L.A., M.T. Trivett, D. Wallace, J. Higgins, M. Baseler, M. Terabe, I.M. Belyakov,, J.A. Berzofsky, and Allan Hildesheim. 2005. Fixation and Cryopreservation of Whole Blood and Isolated Mononuclear Cells: Influence of Different Procedures on Lymphocyte Subset Analysis by Flow Cytometry. Cytometry Part B (Clinical Cytometry): 63B: 47-55.
• 380. Zeng, R., R. Spolski, S.E. Finkelstein, S. Oh, P.E. Kovanen, C.S. Hinrichs, C.A. Pise-Masison, M.F. Radonovich, J.N. Brady, N.P. Restifo, J.A. Berzofsky, and W.J. Leonard. 2005. Synergy of IL-21 and IL-15 in Regulating CD8+ T-Cell Expansion and Function. J Exp Med 201: 139-148. 
• 381. De Groot, A.S., H. Sbai, W. Martin, J. Sidney, A. Sette, and J.A. Berzofsky. 2004. High-throughput informatics and in vitro assays for T-cell epitope determination: application to the design of epitope-driven vaccines. In New Generation Vaccines, Third Edition, Revised and Expanded. M.M. Levine, J.B. Kaper, R. Rappauoli, M.A. Liu, and M.F. Good, editors. Marcel Dekker, Inc., New York. 179-196.
• 382. Park, J.M., M. Terabe, Y. Sakai, J. Munasinghe, G. Forni, J.C. Morris, and J.A. Berzofsky. 2005. Early Role of CD4+ Th1 cells and antibodies in HER-2 adenovirus-vaccine protection against autochthonous mammary carcinomas. J Immunol 174: 4228-4236..
• 383. De Groot, A.S., and J.A. Berzofsky. 2004. From genome to vaccine--new immunoinformatics tools for vaccine design. Methods 34:425-428.
• 384. Carbone, D.P., I.F. Ciernik, M.J. Kelley, M.C. Smith, S. Nadaf, D. Kavanaugh, V.E. Maher, M. Stipanov, D. Contois, B.E. Johnson, C.D. Pendleton, B. Seifert, C. Carter, E.J. Read, J. Greenblatt, L.E. Top, M.I. Kelsey, J.D. Minna, and J.A. Berzofsky. 2005. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J. Clin. Oncol. 23: 5099-5107..
• 385. Bukreyev, A., I.M. Belyakov, G.A. Prince, K.C. Yim, K.K. Harris, J.A. Berzofsky, and P.L. Collins. 2005. Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a non-functional cytotoxic T lymphocyte response following primary infection but not following challenge with wild-type virus. J Virol. 79: 9515-9526.
• 386. Dong, Y., J. Qian, R. Ibrahim, J.A. Berzofsky, and S. Khleif. 2005. CTLs alone elicited by peptide vaccine targeting mouse VEGFR2 inhibit angiogenesis and tumor growth. J. Immunother. 29: 32-40.
• 387. Zhang, H., K.S. Chua, M. Guimond, V. Kapoor, M.V. Brown, T.A. Fleisher, L.M. Long, D. Bernstein, B.J. Hill, D.C. Douek, J.A. Berzofsky, C.S. Carter, E.J. Read, L.J. Helman, and C.L. Mackall. 2005. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4(+)CD25(+) regulatory T cells. Nat Med., 11: 1238-1243.
• 388. van den Broeke, L.T., C.D. Pendleton, C. Mackall, L.J. Helman, and J.A. Berzofsky. 2006. Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. Cancer Research 66: 1818-1823.
• 389. Wang, Y.E., C. Zhang, J.A. Berzofsky and C. DeLisi. 2005. Selecting stable molecular targets for treatment and prevention of AIDS. Genome Informatics 16: 254-261.
• 390. Terabe, M., J. Swann, E. Ambrosino, P. Sinha, S. Takaku, Y. Hayakawa, D.I. Godfrey, S. Ostrand-Rosenberg, M.J. Smyth, and J.A. Berzofsky. 2005. A nonclassical non-V14J18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 202:1627-1633. 
• 391. Belyakov, I.M., V.A. Kuznetsov, B. Kelsall, D. Klinman, M. Moniuszko, M. Lemon, P.D. Markham, P. Pal, J.D. Clements, M.G. Lewis, S. Strober, G. Franchini, and J.A. Berzofsky. 2006. Impact of vaccine-induced mucosal high avidity CD8+ CTL in delay of AIDS-viral dissemination from mucosa. Blood 107: 3258-3264. (published on-line 2005)
• 392. Qian, J., Y. Dong, Y.Y. Pang, R. Ibrahim, J. Berzofsky, J.T. Schiller, and S.N. Khleif. 2006. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. Internat. J. Cancer, 118: 3022-3029.
• 393. Okazaki, T., C. D. Pendleton, P. Sarobe, E. K. Thomas, S. Iyengar, C. Harro, D. Schwartz and J. A. Berzofsky. 2006. Epitope-enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine. J. Immunol., 176: 3753-3759.
• 394. Pal, R., D. Venzon, S. Santra, V.S. Kalyanaraman, D.C. Montefiori, L. Hocker, L. Hudacik, N. Rose, J. Nacsa, E.-S. Y., I.M. Belyakov, J.A. Berzofsky, R. Washington Parks, P. Markham, N.L. Letvin, J. Tartaglia, and G. Franchini. 2006. Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4+ T Cell Loss and Reduces Both Systemic and Mucosal SHIVKU2 RNA Levels. Journal of Virology 80: 3732-3742.
• 395. Terabe, M., C. Khanna, S. Bose, F. Melchionda, A. Mendoza, C.L. Mackall, L. Helman, and J.A. Berzofsky. 2006. CD1d-restricted NKT cells can down-regulate tumor immunosurveillance independent of IL-4R-STAT6 or TGF-. Cancer Research 66: 3869-3875.
• 396. Kawakami, K., M. Terabe, M. Kawakami, J.A. Berzofsky, and R.K. Puri. 2006. Characterization of a novel human tumor antigen IL-13R2 chain. Cancer Research 66:4434-4442.
• 397. Kotelkin, A., I.M. Belyakov, L. Yang, J.A. Berzofsky, P.L. Collins, and A. Bukreyev. 2006. The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T cell response as a consequence of suppressing the type I interferon response. J Virol 80: 5958-5967.
• 398. Kawakami, K., M. Terabe, M. Kioi, J.A. Berzofsky, and R.K. Puri. 2006. Intratumoral Therapy with IL13-PE38 Results in Effective CTL-mediated Suppression of IL-13R alpha 2-Expressing Contralateral Tumors. Clin Cancer Res 12: 4678-4686
• 399. Belyakov, I.M., A. Dzutsev, Q. Zhu, D. Isakov, D. Klinman, and J.A. Berzofsky. 2006. Enhancement of CD8+ T cell immunity in the lung by CpG ODN increases protective efficacy of a Modified Vaccinia Ankara vaccine against lethal poxvirus infection even in CD4-deficient host. J Immunol 177: 6336-6343.
• 400. Okazaki, T., M. Terabe, A.T. Catanzaro, C.D. Pendleton, R. Yarchoan, and J.A. Berzofsky. 2006. Possible therapeutic vaccine strategy against HIV escape from RT inhibitor studied in HLA-A2 transgenic mice. J Virol 80: 10645-10651.
• 49
• 401. Oh, S., B. Stegman, C.D. Pendleton, M.O. Ota, C.H. Pan, D.E. Griffin, D.S. Burke, and J.A. Berzofsky. 2006. Protective immunity provided by HLA-A2 epitopes for fusion and hemagglutinin proteins of measles virus. Virology 352:390-399.
• 402. Pinto, L.A., P.E. Castle, R.B. Roden, C.D. Harro, D.R. Lowy, J.T. Schiller, D. Wallace, M. Williams, W. Kopp, I.H. Frazer, J.A. Berzofsky, and A. Hildesheim. 2005. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine 23:3555-3564.
• 403. Berzofsky, J.A., S. Oh, and M. Terabe. 2005. Peptide vaccines against cancer. Cancer Treat Res 123:115-136.
• 404. Pinto, L.A., R. Viscidi, C.D. Harro, T.J. Kemp, A.J. Garcia-Pineres, M. Trivett, F. Demuth, D.R. Lowy, J.T. Schiller, J.A. Berzofsky, and A. Hildesheim. 2006. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 353:451-462.
• 405. Ota, M.O., Z. Ndhlovu, S. Oh, S. Piyasirisilp, J.A. Berzofsky, W.J. Moss, and D.E. Griffin. 2007. The hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8+ T cell response during measles and after vaccination. J Infect Dis 195: 1799-1807.
• 406. Dzutsev, A. H., I. M. Belyakov, D. V. Isakov, D. H. Margulies, and J. A. Berzofsky. 2007. Avidity of CD8 T-cells sharpens immunodominance. Internat Immunol, 19: 497-507.
• 407. Belyakov, I.M., D.V. Isakov, Q. Zhu, A.H. Dzutsev, and J.A. Berzofsky. 2007. A Novel Functional CTL Avidity/Activity Compartmentalization to the Site of Mucosal Immunization Contributes to Protection of Macaques Against SHIV Viral Depletion of Mucosal CD4+ T cells. J. Immunol. 178: 7211-7221.
• 408. Toubaji, A., S. Hill, M. Terabe, J. Qian, T. Floyd, M. Simpson, J.A. Berzofsky, and S.N. Khleif. 2007. The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine 25: 5882-2891.
• 409. Perera, P.L., J. Mosca, S. Oh, J.A. Berzofsky, and T.A. Waldmann. 2007. Development of smallpox vaccine candidates with integrated IL-15 that demonstrate superior immunogenicity, efficacy and safety in mice. J. Virol. 81: 8774-8783.
• 410. Ambrosino, E., M. Terabe, R.C. Halder, J. Peng, S. Takaku, S. Miyake, T. Yamamura, V. Kumar, and J.A. Berzofsky. 2007. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: A new immunoregulatory axis. J Immunol 179: 5126-5136.
• 411. Terabe, M., and J.A. Berzofsky. 2007. NKT cells in immunoregulation of tumor immunity: cross-regulation between two subsets. Trends in Immunol 28: 491-496.
• 50
• 412. Garcıa-Pineres, A.J. A. Hildesheim, R. Herrero, M. Trivett, M. Williams, I. Atmetlla, M. Ramırez, M. Villegas, M. Schiffman, A. C. Rodrıguez, R. D. Burk, M. Hildesheim, E. Freer, J. Bonilla, C. Bratti, J. A. Berzofsky, and L. A. Pinto. 2006. Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Research 66: 11070-11076.
• 413. Belyakov, I.M., S. Kozlowski, M. Mage, J.D. Ahlers, L.F. Boyd, D.H. Margulies, and J.A. Berzofsky. 2007. Role of α3 domain of class I MHC molecules in the activation of high and low avidity CD8+ cytotoxic T lymphocytes. International Immunology 19: 1413-1420.
• 414. Park, J.M., M. Terabe, D.A. Donaldson, G. Forni, and J.A. Berzofsky. 2008. Natural Immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. Cancer Immunol. Immunother. 57: 907-912.
• 415. Wyatt, L.S., I.M. Belyakov, P.L. Earl, J.A. Berzofsky, and B. Moss. 2008. Enhanced cell surface expression, immungenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. Virology 372: 260-272.
• 416. Berzofsky, J.A., I.J. Berkower, and S.L. Epstein. 2008. Chapter 5: Antigen-antibody interactions and monoclonal antibodies. In Fundamental Immunology 6th Edition. W.E. Paul, editor. Lippincott Williams & Wilkins, Philadelphia. 152-191.
• 417. Berzofsky, J.A., and I.J. Berkower. 2008. Chapter 21: Immunogenicity and antigen structure. In Fundamental Immunology 6th Edition. W.E. Paul, editor. Lippincott Williams & Wilkins, Philadelphia. 631-683.
• 418. Dzutsev, A.K., I. M. Belyakov, D. V. Isakov, S. J. Gagnon, D. H. Margulies, and J. A. Berzofsky. 2008. Estimation of low frequency antigen presenting cells with a novel RELISPOT assay. J. Immunol. Methods 333: 71-78.
• 419. Park, J.M., M. Terabe, J. C. Steel, G. Forni, Y. Sakai, J. C. Morris, and Jay A. Berzofsky. 2008. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine. Cancer Research 68: 1979-1987.
• 420. Berzofsky, J.A., and M. Terabe. 2008. NKT cells in tumor immunity: Opposing subsets define a new immunoregulatory axis. J. Immunol. 180: 3627-3635.
• 421. Berzofsky, J.A., and M. Terabe. 2008. A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunology & Immunotherapy 57: 1679-1683.
• 422. Ambrosino, E., J.A. Berzofsky, and M. Terabe. 2008. Regulation of tumor immunity: the role of NKT cells. Expert Opinion on Biological Therapy 8: 725-734.
• 423. Mackall, C.L., E.H. Rhee, E.J. Read, H.M. Khuu, S.F. Leitman, D. Bernstein, M. Tesso, L. M. Long, D. Grindler, M. Merino, W. Kopp, M. Tsokos, J.A. Berzofsky, and L. J. Helman. 2008. A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric
• 51
• Sarcomas. Clinical Cancer Research, 14: 4850-4858.
• 424. Fichtner-Feigl, S., M. Terabe, A. Kitani, C. A. Young, I. Fuss, E. K. Geissler, H.-J. Schlitt, J. A. Berzofsky, and W. Strober. 2008. Restoration of Tumor Immune Surveillance via Targeting of IL-13Receptor-2. Cancer Research, 68: 3467-3476.
• 425. Oh, S., L. P. Perera, M. Terabe, L. Ni, T. A. Waldmann, and J. A. Berzofsky. 2008. IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc. Natl. Acad. Sci. USA 105: 5201-5206.
• 426. Terabe, M., Y. Tagaya, Q. Zhu, L. Granger, M. Roederer, T. A. Waldmann, and J. A. Berzofsky. 2008. IL-15 expands unconventional CD8NK1.1+ T cells but not V14J18+NKT cells. J. Immunol. 180: 7276-7286.
• 427. Nam, J-S., M. Terabe, M. Mamura, M.-J. Kang, H. Chae, C. Stuelten, E. Kohn, B. Tang, H. Sabzevari, M. R. Anver, S. Lawrence, D. Danielpour, S. Lonning, J. A. Berzofsky, and L. M. Wakefield. 2008. An anti–Transforming Growth Factor  antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Research 68: 3835-3843.
• 428. Nam, J.-S. M. Terabe, M.-J. Kang, H. Chae, N. Voong, Y.-a. Yang, A. Laurence, A. Michalowska, M. Mamura, S. Lonning, J. A. Berzofsky, and L. M. Wakefield. 2008. Transforming Growth Factor  subverts the immune system into directly promoting tumor growth through interleukin 17. Cancer Research, 68:3915-3923.
• 429. Wu, Z., H.-H. Xue, J. Bernard, R. Zeng, D. Issakov, J. Bollenbacher-Reilley, I. M. Belyakov, S. Oh, J. A. Berzofsky and W. J. Leonard. 2008. The IL-15 receptor α chain cytoplasmic domain is critical for normal IL-15Rα function but is not required for trans-presentation. Blood , 112: 4411-4419.
• 430. Belyakov, I. M., J. D. Ahlers, G. J. Nabel, B. Moss, and J. A. Berzofsky. 2008. Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic, or mixed prime-boost immunization. Virology 381: 106-115.
• 431. Epel, M., I. Carmi, S. Soueid-Baumgarten, SK. Oh, T. Bera, I. Pastan, J. Berzofsky, and Y. Reiter. 2008. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur J Immunol. 38:1706-1720.
• 432. Terabe, M. and J. A. Berzofsky. 2008. The role of NKT cells in tumor immunity. Advances in Cancer Research 101: 277-348.
• 433. Hall, J.A., N. Bouladoux, C.M. Sun, E.A. Wohlfert, R.B. Blank, Q. Zhu, M.E. Grigg, J.A. Berzofsky, and Y. Belkaid. 2008. Commensal DNA Limits Regulatory T Cell Conversion and Is a Natural Adjuvant of Intestinal Immune Responses. Immunity 29: 637-649.
• 52
• 434. Zhu, Q., C. Egelston, A. Vivekanandhan, S. Uematsu, S. Akira, D. M. Klinman, I. M. Belyakov, and J. A. Berzofsky. 2008. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc. Natl. Acad. Sci. USA, 105: 16260-16265.
• 435. Berzofsky, J.A., and M. Terabe. 2009. The contrasting roles of NKT cells in tumor immunity. Current Molecular Medicine 9: 667-672.
• 436. Terabe, M., & J. A. Berzofsky. NKT cells and cancer: two subsets form a new immunoregulatory axis. American Association of Cancer Research Educational Book 2009.
• 437. Isakov, D., A. Dzutsev, I. M. Belyakov, and J. A. Berzofsky. 2009. Non-equilibrium and differential function between Intraepithelial and Lamina Propria TCR+ CD8+ T Cells In The Small Intestinal Mucosa. Mucosal Immunology, 2: 450-461.
• 438. Oakley, M.S., V. Majam, B. Mahajan, N. Gerald, V. Anantharaman, J. M. Ward, L. J. Faucette, T. F. McCutchan, H. Zheng, M. Terabe, J. A. Berzofsky, L. Aravind, S. Kumar. 2009. Pathogenic roles of CD14, galectin 3, and Ox40 during experimental cerebral malaria in mice. PLoS ONE, 4: e6793.
• 439. Terabe, M., A. Ambrosino, S. Takaku, D. Venzon, S. Lonning, J. M. McPherson, and Jay A. Berzofsky. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-TGF-β monoclonal antibody. 2009. Clinical Cancer Research 15: 6560-6569.
• 440. Zhu, Q., C. Egelston, S. Gagnon, Y. Sui, I. M. Belyakov, D. M. Klinman, and J. A. Berzofsky. Using three TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. 2010. J. Clin. Invest. 120: 607-616.
• 441. Takaku, S., M. Terabe, E. Ambrosino, J. Peng, S. Lonning, J. M. McPherson, and J. A. Berzofsky. Blockade of TGF- enhances tumor vaccine efficacy mediated by CD8+ T cells. 2010. Internat. J. Cancer 126: 1666-1674.
• 442. Sui, Y., Q. Zhu, S. Gagnon, A. Dzutsev, M. Terabe, M. Vaccari, D. Venzon, D. Klinman, W. Strober, B. Kelsall, G. Franchini, I. M. Belyakov, and J. A. Berzofsky. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. 2010. Proc. Natl. Acad. Sci. USA, 107: 9843-9848. (published on line, May, 2010).
• 443. Rahma, O. E., E. Ashtar, R. Ibrahim, A. Toubaji, B. Gause, V. E. Herrin, W.M. Linehan, S. M. Steinberg, F. Grollman, G. Grimes, S. A. Bernstein, J. A. Berzofsky and S. N. Khleif. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. 2010. J. Translat. Med., 8:8-16.
• 444. O’Konek, J.J., M. Terabe, and J. A. Berzofsky. The role of NKT cells in the immune regulation of neoplastic disease. In: Rongfu Wang, Editor. Innate and adaptive immune
• 53
• regulation and cancer immunotherapy. Springer, NY. In press. 2010.
• 445. De Groot, A.S., T. Cohen, M. Ardito, L. Moise, B. Martin, and J. A. Berzofsky. Use of bioinformatics to predict MHC ligands and T-cell epitopes: application to epitope-driven vaccine design. 2010. Methods in Microbiology 37: 35-66.
• 446. O’Konek, J., P. Illarionov, D. Stewart Khursigara, E. Ambrosino, L. Izhak, B. F. Castillo II, R. Raju, M. Khalili, H.-Y. Kim, A. R. Howell, G. S. Besra, S. A. Porcelli, J. A. Berzofsky and M. Terabe. . Novel agonist of mouse and human iNKT cells reveals a new mechanism of tumor immunity. J. Clin. Invest. 121: 683-694.
• 447. Sui, Y. and J. A. Berzofsky. 2011. Vaccine strategies to prevent mucosal transmission of HIV-1. In Novel Approaches to Vaccine Research, 2011, Kathleen L. Hefferon, editor. ISBN: 978-81-308-0449-1. Research Signpost, Kerala. 137-180.
• 448. Lai, D., J. Zhu, T. Wang, J. Hu-Li, M. Terabe, J. A. Berzofsky, C. Clayberger, and A. M. Krensky. 2011. KLF13 sustains thymic memory-like CD8+ T cells in BALB/c mice by regulating IL-4-generating invariant natural killer T cells. J. Exp. Med. 208: 1093-1103. (online April, 2011)
• 449. O’Konek, J., J. A. Berzofsky, and M. Terabe. 2012. Immune regulation of tumor immunity by NKT cells. In Masaki Terabe and Jay A. Berzofsky, Editors. Natural Killer T cells: Setting the Balance in the Regulation of Tumor Immunity. Springer, NY. Pp 55-70.
• 450. Yu, H., A. Tawab-Amiri, A. Dzutsev, M. Sabatino, K. Aleman, R. Yarchoan, M. Terabe, Y. Sui, and J. A. Berzofsky. 2011. IL-15 ex vivo overcomes CD4+ T cell deficiency for the induction of human antigen-specific CD8+ T cell responses. J. Leuk. Biol. 90: 205-214. (online April, 2011).
• 451. Rahma, O.E., E. Achtar, M. Czystowska, M. E. Szajnik, E. Wieckowski, S. Bernstein 1, V. E. Herrin, M. A. Shams, S. M. Steinberg, M. Merino, W. Gooding, C. Visus, A. B. DeLeo, J. K. Wolf, J. G. Bell, J. A. Berzofsky, T. L. Whiteside, and S. N. Khleif. 2012. A Gynecologic Oncology Group phase II trial comparing p53 peptide subcutaneous injection and intravenous pulsed dendritic cells in high-risk ovarian cancer patients. Cancer Immunology Immunotherapy 61: 373-384.
• 452. Nakashima, H., M. Terabe, J. A. Berzofsky, S. R. Husain1, and R. K. Puri. 2011. A Novel combination immunotherapy for cancer by IL-13 receptor alpha2 targeted DNA vaccine and immunotoxin in murine tumor models. J. Immunol. 187: 4935-4946.
• 453. Isakov, D., A. Dzutsev, J. A. Berzofsky, and I. M. Belyakov. 2011. Lack of IL-7 and IL-15 signaling affects interferon-gamma production by, more than survival of, small intestinal intraepithelial memory CD8+ T cells. Eur. J. Immunol. 41: 3513-3528.
• 454. Terabe, M., and J. A. Berzofsky (editors). Natural Killer T cells: Balancing the regulation of tumor immunity. 2012. Springer, New York. ISBN 978-1-4614-0612-9. 
• 455. Sui, Y., S. Gagnon, A. Dzutsev, Q. Zhu, H. Yu, A. Hogg, Y. Wang, Z. Xia, I. M. Belyakov, D. Venzon, D. Klinman, W. Strober, B. Kelsall, G. Franchini, and J. A. Berzofsky. 2011. TLR agonists and/or IL-15 adjuvanted mucosal SIV-vaccine reduced gut CD4+ memory T cell loss in SIVmac251-challenged rhesus macaques. Vaccine 30: 59-68.
• 456. Berzofsky, J. A. 2011. A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses. Vaccine, doi: 10.1016/j.vaccine.2011.11.034.
• 457. Berzofsky, J. A., M. Terabe, and L. V. Wood. 2011. Strategies to use immune modulators in therapeutic vaccines against cancer. Seminars in Oncology 39: 348-357.
• 458. Berzofsky, J. A., and I. J. Berkower. 2012. Antigen-antibody interactions and monoclonal antibodies. In Fundamental Immunology 7th edition. W.E. Paul, editor. Lippincott Williams & Wilkins, Philadelphia. In press.
• 459. Berzofsky, J. A., and I. J. Berkower. 2012. Immunogenicity and antigen structure. In Fundamental Immunology 7th edition. W.E. Paul, editor. Lippincott Williams & Wilkins, Philadelphia. In press.
• 460. Zhu, Q., J. Talton, G. Zhang, T. Cunningham, Z. Wang, R. C. Waters, J. Kirk, B. Eppler, D. M. Klinman, I. M. Belyakov, Y. Sui, S. Gagnon, R. J. Mumper, and J. A. Berzofsky. 2012. Large intestine-targeted nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nature Medicine 18: 1291-1296.
• 461. Berzofsky, J. A. 2012. Improving immunotherapy: Revisiting the immunologist’s little secret. Science Translational Medicine, 4 (120): 1-3.
• 462. Sui, Y.*, S. Gordon*, G. Franchini**, and J. A. Berzofsky**. 2013. Non-human primate models for HIV/AIDS vaccine development. Current Protocols in Immunology, 12.14.1-12.14.30. (*; **, Contributed equally).
• 463. Izhak, L., E. Ambrosino, S. Kato, S. T. Parish, J. J. O’Konek, H. Weber, Z. Xia, D. Venzon, J. A. Berzofsky, and M. Terabe. 2013. Delicate balance among three types of T cells in concurrent regulation of tumor immunity. Cancer Research 73: 1514-1523.
• 464. Ben-Sasson, S. Z., A. Hogg, J. Hu-Li, P. Wingfield, X. Chen, M. Crank, S. Caucheteux, M. Ratner-Hurevich, J. A. Berzofsky, R. Nir-Paz, and W. E. Paul. 2013. IL-1 enhances expansion, effector function, tissue localization and memory response of antigen-specific CD8 T cells. J. Exp. Med. 210: 491-502.
• 465. Zhu, Q, and J. A. Berzofsky. 2013. Oral vaccines: directed safe passage to the front line of defense. Gut Microbes 4: 1-7.
• 466. Izhak, L., J. A. Berzofsky, and M. Terabe. 2013. Balance is a key for happiness. Oncoimmunology, e24211.
• 467. Huang, Y.-H., M. Terabe, C. D. Pendleton, D. Stewart Khursigara, T. Bera, I. Pastan, and J. A. Berzofsky. 2013. Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE. PLOS ONE 8 (6): e64365.
• 468. O’Konek, J. J., S. Kato1, S. Takao, Liat Izhak, Z. Xia, P. Illarionov, G. S. Besra, M. Terabe and J. A. Berzofsky. 2013. -mannosylceramide activates type I natural killer T cells to induce tumor immunity without inducing long-term functional anergy. Clinical Cancer Research, 19: 4404-4411.
• 469. Berzofsky, J.A., L. V. Wood, and M. Terabe. 2013. Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer. Expert Review of Vaccines, 12: 1115-1118.
• 470. Vargas-Inchaustegui, D.A., P. Xiao, A. E. Hogg, T. Demberg, K. McKinnon, D. Venzon, E. Brocca-Cofano, J. DiPasquale, E. M. Lee, L. Hudacik, R. Pal, Y. Sui, J. A. Berzofsky, L. Liu, S. Langermann, and M. Robert-Guroff. 2013. Immune Targeting of PD-1hi Expressing Cells During and After Antiretroviral Therapy in SIV-infected Rhesus Macaques. Virology, 447: 274-284.
• 471. Terabe, M., and J. A. Berzofsky. 2014. The immunoregulatory role of type I and type II NKT cells in cancer and other diseases. Cancer Immunology, Immunotherapy, 63: 199-213.
• 472. Morris, J. C., A. R. Tan, T. E. Olencki, G. I. Shapiro, B. J. Dezube, M. Reiss, F. J. Hsu, J. A. Berzofsky, and D. P. Lawrence. 2014. Phase I Study of GC1008 (Fresolimumab): A Human Anti-transforming Growth Factor-beta (TGF) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma. PLoS One, Mar 11;9(3):e90353. doi: 10.1371/journal.pone.0090353.
• 473. Berzofsky, J. A., and G. Franchini. 2015. Human/simian immunodeficiency virus transmission and infection at mucosal sites. In Mucosal Immunology, 4th Edition, Mestecky, J., W. Strober, M. W. Russell, B. L. Kelsall, H. Cheroutre, and B.N. Lambrecht, editors. Elsevier, Amsterdam, 1481-1492.
• 474. Sui, Y., A. Hogg , Y. Wang, B. Frey, H. Yu, Z. Xia, D. Venzon, K. McKinnon, J. Smedley, M. Gathuka, D. Klinman, B. F. Keele, S. Langermann, L. Liu, G. Franchini, and J. A. Berzofsky. 2014. Mucosal adjuvants and myeloid cells modulate viral load reduction in SIVmac251 infection of macaques. J. Clin. Invest. 124: 2538-2549. (published on line May 2014 doi:10.1172/JCI73518).
• 475. Chen, Z., L. Ozbun, N. Chong, A. Wallecha, J. A. Berzofsky, and S. N. Khleif. 2014. Episomal expression of truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansion of CD4+Foxp3- and CD8+ T cells. Cancer Immunology Research 2: 911-922.
• 476. Vargas-Inchaustegui, D., I. Tuero, V. Mohanram, T. Musich, P. Pegu, A. Valentin, Y. Sui, M. Rosati, J. Beal, D. J. Venzon, V. Kulkarni, C. Alicea, G. R. Pilkington, N. P. M. Liyanage, T. Demberg, S. N. Gordon, Y. Wang, A. E. Hogg, B. Frey, L. J. Patterson, J.  DiPasquale, D. Montefiori, N. Sardesai, S. G. Reed, J. A. Berzofsky, G. Franchini, B. K. Felber, G. N. Pavlakis, and M. Robert-Guroff. 2014. Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggest novel combinatorial approaches for enhancing responses. Clinical Immunology 153: 308-322.
• 477. Abu-Eid, R., R. N. Samara, L. Ozbun, K. M. Friedman, J. A. Berzofsky, M. Mkrtichyan, and S. N. Khleif. 2014. Selective inhibition of regulatory T cells by targeting PI3K-Akt pathway. Cancer Immunology Research 2: 1080-1089. Doi: 10.1158/2326-6066.CIR-14-0095.
• 478. Valentin, A., K. McKinnon, J. Li, M. Rosati, V. Kulkarni, G. R Pilkington, J. Bear, C. Alicea, D. A Vargas-Inchaustegui, L. J. Patterson, P. Pegu, N. P.M. Liyanage, S. N Gordon, M. Vaccari, Y. Wang, A. E Hogg, B. Frey, Y. Sui, S. G Reed, N. Y. Sardesai, J. A. Berzofsky, G. Franchini, M. Robert-Guroff, B. K Felber, and G. N. Pavlakis. 2014. Comparative Analysis of SIV-specific Cellular Immune Responses Induced by Different Vaccine Platforms in Rhesus Macaques. Clinical Immunology 155: 91-107. Doi: 10.1016/j.clim.2014.09.005.
• 479. Soto-Pantoja, D. R., M. Terabe, A. Ghosh, L. A. Ridnour, W. G. DeGraff, D. A. Wink, J. A. Berzofsky, and D. D. Roberts. 2014. CD47 in the tumor microenvironment limits cooperation between anti-tumor T cell immunity and radiation therapy. Cancer Research 74: 6771-6783. Doi: 10.1158/0008-5472.CAN-14-0037-T.
• 480. Robertson, F. C., J. A. Berzofsky, and M. Terabe. 2014. NKT cell networks in the regulation of tumor immunity. Frontiers in Immunology 5: 553 article 543. Doi: 10.3389/fimmu.2014.00543.
• 481. Lacouture,, M. E., J. C. Morris, D. P. Lawrence, A. R. Tan, T. E. Olencki, G. I. Shapiro, B. J. Dezube, J. A. Berzofsky, F. J. Hsu, and J. Guitart. 2015. Cutaneous lesions associated with neutralization of TGF by the monoclonal antibody GC1008. Cancer Immunology, Immunotherapy, 64: 437-446. DOI 10.1007/s00262-015-1653-0 (Jan, 2015).
• 482. Wang, Y. Y. Sui, S. Kato, A. E. Hogg, J. C. Steel, J. C. Morris and J. A. Berzofsky. 2015. Vaginal type-II mucosa is an inductive site for primary CD8+ T cell mucosal immunity. Nature Communications 6:6100; DOI: 10.1038/ncomms7100. Pub online Jan 20, 2015.
• 483. Kapanadze, T., J. Medina-Echeverz, J. Gamrekelashvili, J. M. Weiss, R. H. Wiltrout, V. Kapoor, N. Hawk, M. Terabe, J. A. Berzofsky, M. P. Manns, E. Wang, F. M. Marincola, F. Korangy, T. F. Greten. 2015. Tumor induced CD11b+ Gr-1+ myeloid derived suppressor cells exacerbate immune mediated hepatitis in mice in a CD40-dependent manner. Eur. J. Immunol., 45: 1148-1158.
• 484. Jing, W., Y. Shirota, D. Bayik, H. Shirota, D. Tross, J. L. Gulley, L. Wood, J. A. Berzofsky, and D. Klinman. 2015. Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells. J. Immunol., 194: 4215-4221.
• 485. Rahma, O.E., V. E. Herrin, R. A. Ibrahim, A. Toubaji, S. Bernstein, O. Dakheel, S. M. Steinberg, R. Eid, M. Mkrtichyan, J. A. Berzofsky and S. N. Khleif. 2014. Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer. J. Translational Med. 12: 353-362.
• 486. Berzofsky, J.A., L. V. Wood, and M. Terabe. 2015. Strategies for improving vaccines to elicit T cells to treat cancer. In: Developments in T cell based cancer immunotherapies. E. Wang, P. Ascierto, and D. Stroncek, editors. Springer, New York. Chapter 2, 29-52.
• 487. Terabe, M., and J.A. Berzofsky. 2015. NKT cells in tumor immunity. In: Encyclopedia of Immunobiology. M. Ratcliffe, editor. Elsevier. In press.
• 488. Solaymani-Mohammadi, S., O.Lakhdari, I. Minev, S. Shenouda, B. F. Frey, R. Billeskov, S. M. Singer, J. A. Berzofsky, L. Eckmann, and M. F. Kagnoff. 2016. Lack of the programmed death-1 receptor renders host susceptible to enteric microbial infection through impairing the production of the mucosal natural killer cell effector molecules. J. Leukocyte Biol. 99: 475-482.
• 489. Sui, Y., E. M. Lee, Y. Wang, A. Hogg, B. Frey, D. Venzon, R. Pal, and J. A. Berzofsky. 2016. Early SIV dissemination after intra-rectal SIVmac251 challenge was associated with proliferating virus-susceptible cells in the colorectum. J. AIDS 71: 353-358.
• 490. Yu, H., Y. Sui, Y. Wang, N. Sato, B. Frey, Z. Xia, T. A Waldmann, and J. A Berzofsky. 2015. Interleukin-15 constrains mucosal T helper 17 cell generation: influence of mononuclear phagocytes. PLoS One 10: e0143001. DOI:10.1371/journal.pone.0143001.
• 491. Parchment, R. E., A. R. Voth, J. H. Doroshow, and J. A. Berzofsky. 2016. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. Seminars in Oncology 43: 501-513.
• 492. Zdanov, S. M. Mandapathil, R. Abu Eid, S. Adamson-Fadeyi, W. Wilson, J. Qian, A. Carnie, N Tarasova, M. Mkrtichyan, J. A. Berzofsky, T. L. Whiteside, and S. N. Khleif. 2016. Mutant KRAS conversion of conventional T cells into regulatory T cells. Cancer Immunology Research 4: 354-365.
• 493. Wood, L. V., T. Fojo, B. D. Roberson, M. S. B. Hughes, W. Dahut, J. L. Gulley, R. A. Madan, P. M. Arlen, M. Sabatino, D. F. Stroncek, L. Castiello, J. B. Trepel, M.-J. Lee, H. L. Parnes, S. M. Steinberg, M. Terabe, J. Wilkerson, I. Pastan, and J. A. Berzofsky. 2016. TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with stage D0 prostate cancer. OncoImmunology, DOI: 10.1080/2162402X.2016.1197459.
• 494. Castiello, L., M. Sabatino, J. Ren, M. Terabe, H. Khuu, L.V. Wood, J.A. Berzofsky, and D.F. Stroncek. 2017. Expression of CD14, IL-10 and tolerogenic signature in dendritic cells inversely correlate with response to TARP vaccination in prostate cancer patients.   Clinical Cancer Research, 23: 3352-3364.
• 495. Gulley, J. L., J. A. Berzofsky, M. O. Butler, A. Cesano, B. A. Fox, S. Gnjatic, S. Janetzki, S. Kalavar, V. Karanikas, S. N. Khleif, I. Kirsch, P. P. Lee, C. Maccalli, H. Maecker, J. Schlom, B. Seliger, J. Siebert, D. F. Stroncek, M. Thurin, J. Yuan, and L. H. Butterfield. 2017. Immunotherapy Biomarkers 2016: Overcoming the Barriers. Journal for ImmunoTherapy of Cancer, 5:29.
• 496. Billeskov, R., Y. Wang, S. Solaymani-Mohammadi, B. Frey, S. Kulkarni, P. Andersen, E. M. Agger, Y. Sui, and J. A. Berzofsky. 2017. Low antigen dose in adjuvant-based vaccination selectively induces CD4 T cells with enhanced functional avidity and protective efficacy. J. Immunol., 198: 3494-3506.
• 497. Terabe, M., Clark, K., Robertson, F.C., De Ravin, E., Bloom, A., Venzon, D., Kato, S., Mirza, A.M., Berzofsky, J.A. 2017. Blockade of only TGF-beta 1 & 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. OncoImmunology, 6:5, e1308616, DOI: 10.1080/2162402X.2017.1308616.
• 498. Morales-Kastresana, A., Telford, W., Musich, T., McKinnon, K., Clayborne, C., Braig, Z., Rosner, A., Demberg, T., Watson, D., Karpova, T.S., Freeman, G.J., DeKruyff, R.H., Pavlakis, G., Terabe, M., Robert-Guroff, M., Berzofsky, J.A., Jones, J. 2017. Labeling extracellular vesicles for nanoscale flow cytometry. Scientific Reports, 7: 1878 | DOI:10.1038/s41598-017-01731-2.
• 499. Sui , Y., B. Frey, Y. Wang, R. Billeskov, S. Kulkarni, K. McKinnon, T. Rourke, L. Fritts, C. J. Miller, J. A. Berzofsky. 2017. Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques. PLoS Pathogens, 13(5): e1006395.
• 500. Leshem, Y., Liu, X., Bera, T., Terabe, M., Berzofsky, J.A., Bossenmaier, B., Niederfellner, G., O’Brien, J., Tai, C., Reiter, Y., Pastan, I. 2017. Combining local immunotoxins targeting mesothelin with CTLA-4 blockade synergistically eradicates murine cancer by promoting anti-cancer immunity. Cancer Immunol Research, 5: 685-694.
• 501. Hogg, A., Y. Sui, S. Z. Ben-Sasson, W. E. Paul, and J. A. Berzofsky. 2017. Role of CD4 T cell helper subsets in immune response and deviation of CD8 T cells in mice. Eur J Immunol. 47: 2059-2069.
• 502. Dzutsev, A., Hogg, A., Y. Sui, S. Solaymani-Mohammadi, H. Yu, B. Frey, Y. Wang, and J. A. Berzofsky. 2017. Differential T cell homing to colon vs small intestine is imprinted by local CD11c+ antigen presenting cells that determine homing receptors. J. Leuk. Biol. 102: 1381-1388. (doi:10.1189/jlb.1A1116-463RR).
• 503. Speir, M., A. Authier-Hall, C. R. Brooks, K. J. Farrand, B. J. Compton, R. J. Anderson, A. Heiser, T. L. Osmond, C. W. Tang, J. A. Berzofsky, M. Terabe, G. F. Painter, I. F. Hermans, and R. Weinkove. 2017. Glycolipid-peptide conjugate vaccines enhance CD8+ T cell responses against human viral proteins. Scientific Reports 7:14273.
• 59
• 504. Berzofsky, J. A., M. Terabe, J. B. Trepel, I. Pastan, D. F. Stroncek, J. C. Morris, and L. W. Wood. 2017. Cancer vaccine strategies: translation from mice to human clinical trials. Cancer Immunology, Immunotherapy, DOI 10.1007/s00262-017-2084-x.
• 505. Frey, B., J. Jiang, Y. Sui, L. F. Boyd, B. Yu, G. Tatsuno, R. Billeskov, S. Solaymani-Mohammadi, P. W. Berman, D. H. Margulies, and J. A. Berzofsky. 2018. Effects of cross-presentation, antigen processing, and peptide binding in HIV evasion of T cell immunity. J. Immunol. 200: 1853-1864.
• 506. Kato, S., J. A. Berzofsky, and M. Terabe. 2018. Possible therapeutic application of targeting type II NKT cell-mediated suppression of tumor immunity. Frontiers in Immunology, 9: article 314.
• 507. O’Konek, J. J., E. Ambrosino, A. C. Bloom, L. Pasquet, C. Massilamany, Z. Xia, M. Terabe, and J. A. Berzofsky. 2018. Differential regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin. OncoImmunology, e1439305 published on line April 9, 2018.
• 508. Maeng, H., M. Terabe, and J. A. Berzofsky. 2018. Cancer vaccines: Translation from mice to human clinical trials. Current Opinion in Immunology 51:111-122.
• 509. Jin, P., W. Chen, J. Ren, S. Chen, L. Wood, Y. Zhao, A. Remaley, C. Pham, S. Lian, S. Liu, H. Liu, S. Highfill, J. A. Berzofsky and D. Stroncek. 2018. Plasma from some cancer patients inhibits adenoviral Ad5f35 vector transduction of dendritic cells. Cytotherapy, 20: 728-739.
• 510. Ma, C., M. Han, B. Heinrich, Q. Fu, Q. Zhang, M. Sandhu, D. Agdashian, F. Korangy, M. Terabe, J. A. Berzofsky, V. Fako, T. Ritz, T. Longerich, C. M. Theriot, J. A. McCulloch, S. Roy, W. Yuan, V. Thovarai, S. K. Sen, M. Ruchirawat, X. Wei Wang, G. Trinchieri, and T. F. Greten. 2018. Gut microbiome-controlled bile acid metabolism regulates liver cancer via NKT cells. Science, 360: 876.
• 511. Paquin-Proulx, D., B. C. Greenspun, L. Pasquet, B. Strunz, S. Aleman, K. Falconer, M. Terabe, J. A. Berzofsky, J. K. Sandberg, E. Melum, D. F. Nixon, and N. K. Björkstrom. 2018. IL13R2 identifies tissue-resident IL-22 producing PLZF+ innate T cells in the human liver. Eur. J. Immunol., 48: 1329-1335.
• 512. Sui, Y., A. Dzutsev, D. Venzon, B. Frey, V. Thovarai, G. Trinchieri, and J. A. Berzofsky. 2018. Influence of gut microbiome on mucosal immune activation and SHIV viral transmission in naïve macaques. Mucosal Immunology, 11: 1219-1229.
• 513. Welsh, J. A., J. Kepley, A. Rosner, P. Horak, J. A. Berzofsky, and J. C. Jones. 2018. Prospective use of high-refractive index materials for single molecule detection in flow cytometry. Sensors, 18(8). pii: E2461. doi: 10.3390/s18082461.
• 514. Terabe, M., and J. A. Berzofsky. 2018. Tissue-specific roles of NKT cells in tumor immunity. Frontiers in Immunology, 9:1838. doi: 10.3389/fimmu.2018.01838.
• 515. Billeskov, R., B. Beikzadeh, and J. A. Berzofsky. 2018. The effect of antigen dose on T cell-targeting vaccine outcome. Human Vaccines & Immunotherapeutics, DOI: 10.1080/21645515.2018.1527496.
• 516. Sui, Y., G. Lewis, Y. Wang, K. Berckmueller, B. Frey, A. Dzutsev, D. Vargas-Inchaustegui, V. Mohanram, T. Musich, S. Shen, A. DeVico, T. Fouts, D. Venzon, J. Kirk, C. Waters, J. Talton, J. Clements, G. D. Tomaras, G. Franchini, M. Robert-Guroff, G. Trinchieri, R. C. Gallo, and J. A. Berzofsky. 2019. Mucosal vaccine efficacy against intrarectal SHIV acquisition in the absence of anti-Env antibody. J. Clin. Invest., 129:1314-1328, Published on line Feb 2019, doi.org/10.1172/JCI122110.
• 517. Morales-Kastresana, A., T. A. Musich, J. A. Welsh, W. Telford, T. Demberg, J. C. S. Wood, E. J. Felton, M. Bigos, C. D. Ross, A. Kachynski, A. Dean, J. Van Dyke, J. Tigges, V. Toxavidis, D. R. Parks, W. R. Overton, A. H. Kesarwala, G. J. Freeman, A. Rosner, S. P. Perfetto, L. Pasquet, M. Terabe, K. McKinnon, V. Kapoor, J. B. Trepel, A. Puri, H. Kobayashi, B. Yung, X. Chen, P. Guion, P. Choyke, S. J. Knox, I. Ghiran, M. Robert-Guroff, J. A. Berzofsky, J. C. Jones. 2019. High-fidelity detection and sorting of nanoscale vesicles in viral disease and cancer. J. Extracellular Vesicles, 8: 1, 1597603. DOI: 10.1080/20013078.2019.1597603. Published on line 19 June, 2019.
• 518. Solaymani-Mohammadi, S., and J. A. Berzofsky. 2019. IL-21 collaborates with interferon- for the optimal expression of interferon-stimulated genes and enhances protection against enteric microbial infection. PLoS Pathogens, 15: e1007614. https://doi.org/10.1371/journal.ppat.1007614.
• 519. Maeng, H., and J. A. Berzofsky. 2019. Strategies for developing and optimizing cancer vaccines. F1000Research 2019 (F1000 Faculty Review), published May 13, 2019. 654(https://doi.org/10.12688/f1000research.18693.1)
• 520. Vaccari, M., S. Fourati, D.R. Brown, I. Silva de Castro, M. Bissa, L. Schifanella, M. N. Doster, K. E. Foulds, M. Roederer, R. A. Koup, Y. Sui, J. A. Berzofsky, R.-P. Sekaly, and G. Franchini. 2019. Myeloid cell crosstalk regulates the efficacy of the DNA/ALVAC/gp120 HIV vaccine candidate. Frontiers in Immunology, 10:1072. doi: 10.3389/fimmu.2019.01072. eCollection 2019.
• 521. Bloom, A. C., L. Bender, S. Tiwary, L. Pasquet, K. Clark, T. Jiang, Z. Xia, A. Morales-Kastresana, J. C. Jones, I. Walters, M. Terabe, and J. A. Berzofsky. 2019. Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. OncoImmunology, in press.